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Abstract 
 
In this thesis, patient induced pluripotent stem (iPS) cell-derived neurons and neural cells were used as a model 
for infantile onset spinocerebellar ataxia (IOSCA). IOSCA is an early-onset recessively inherited mitochondrial 
ataxia belonging to the Finnish disease heritage. Patients become progressively severely disabled after disease 
onset and currently no curative treatments exist. IOSCA is caused by a homozygous mutation (Y508C) in the 
mitochondrial helicase Twinkle. Twinkle participates in mitochondrial DNA (mtDNA) replication and the mutant 
helicase has been shown to deplete mtDNA from the brain and liver of patients. The aim of this thesis was to 
obtain IOSCA patient-derived neurons that would manifest a neuronal phenotype related to the disease, and 
analyze molecular and metabolic consequences of the mutant form of Twinkle, to shed light on the pathogenic 
mechanisms underlying symptoms in IOSCA. 
 
Neuronal differentiation of iPS cells was achieved using two different methods: spontaneous differentiation as 
neurospheres in a suspension culture, and an adherent culture using two small molecule inhibitors blocking 
SMAD signaling. IOSCA patient iPS cells were able to differentiate into neurons, from here on called IOSCA 
neurons, using both methods. However, neuronal cultures from IOSCA cell lines differentiated as neurospheres 
had significantly less neurons compared to healthy controls. In addition, the patient-derived neurons were 
shorter and more polar, which could suggest impaired maturation.  
 
Regardless of the differentiation method, IOSCA neurons had reduced mitochondrial networks, especially in 
neurites. The finding was supported by a reduction of mitochondrial respiratory chain complexes I and IV. IOSCA 
neural cells did not show activation of the mitochondrial integrated stress response, folate cycle or serine 
biosynthesis. However, untargeted metabolomics revealed that major metabolic pathways were altered in the 
patient-derived neural cells. Nucleotide, especially purine synthesis was clearly affected, as its intermediates 
comprised a significant group of decreased metabolites. Also core energy metabolic pathways were altered. 
IOSCA neural cells had decreased intermediates of the citric acid cycle, whereas they had accumulated medium 
and long-chain fatty acids. Increased levels of fatty acid synthesis intermediates suggested that the patient-
derived neural cells had shifted their metabolism towards lipid synthesis, or that they were not able to utilize 
fatty acids that were synthesized.  
 
Because the patient-derived neuronal cells revealed differences between patient and control cell lines, they 
could be further utilized to assess therapy options. The impaired nucleotide synthesis could be attempted to be 
alleviated through nucleotide supplementation, and remodeled energy metabolism affected through diet. 
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Abstrakti 
Tässä diplomityössä käytettiin potilaiden indusoiduista monikykyisistä kantasoluista erilaistettuja hermosoluja 
mallina IOSCA-nimiselle (Infantile onset spinocerebellar ataxia) imeväisiässä alkavalle pikkuaivo- ja 
selkäydinperäiselle ataksialle.  IOSCA on peittyvästi periytyvä tauti, joka kuuluu suomalaiseen tautiperintöön. 
Potilaat ovat etenevästi vaikeavammaisia sairastumisensa jälkeen, eikä tautiin ole tällä hetkellä parantavaa 
hoitoa. IOSCA on mitokondriosairaus, jonka aiheuttaa homotsygoottinen mutaatio (Y508C) mitokondriaalista 
helikaasia Twinkleä koodaavassa geenissä. Twinkle osallistuu mitokondriaalisen DNA:n (mtDNA:n) 
monistamiseen ja mutaation on osoitettu johtavan mtDNA:n vähenemiseen potilaiden aivoissa ja maksassa. 
Tämän työn tavoitteena oli erilaistaa potilaiden indusoidut monikykyiset kantasolut hermosoluiksi, jotka 
ilmentäisivät tautiin liittyviä hermoston oireita, sekä analysoida mutatoituneen Twinklen aiheuttamia 
molekulaarisia ja aineenvaihdunnallisia muutoksia, jotta IOSCAn solutasolla vaikuttavia tautimekanismeja 
voitaisi ymmärtää paremmin. 
 
Hermosolujen erilaistamiseen käytettiin kahta eri menetelmää: erilaistusta suspensiossa neurosfeereinä sekä 
adherenttia soluviljelmää, jossa inhiboitiin kahta merkittävää transkriptiotekijää. IOSCA-potilaiden indusoidut 
monikykyiset kantasolut kykenivät erilaistumaan hermosoluiksi (IOSCA-hermosoluiksi) molempia menetelmiä 
käyttäen. Neurosfeereinä erilaistetuissa IOSCA-hermosoluviljelmissä oli kuitenkin merkittävästi vähemmän 
hermosoluja verrattuna terveisiin verrokkeihin. Lisäksi nämä potilasperäiset hermosolut olivat 
haarautuneempia ja lyhyempiä, mikä voisi viitata siihen, että IOSCA-hermosolujen kypsyminen on puutteellista.  
 
Riippumatta erilaistusmenetelmästä mitokondrioiden määrä oli selvästi vähentynyt IOSCA-hermosoluissa, 
erityisesti neuriiteissa. Tulosta vahvisti mitokondrioiden hengitysketjun proteiinikompleksien I ja IV vähentynyt 
määrä. IOSCA-hermosoluissa ei nähty mitokondriaalisen integroidun stressivasteen, folaattisyklin eikä seriinin 
biosynteesin aktivoitumista. Kohdentamaton mataboliittiprofilointi kuitenkin paljasti merkittävien 
aineenvaihduntapolkujen muuttuneen. Nukleotidien, erityisesti puriinien synteesi oli selvästi häiriintynyt, sillä 
suuri osa sen välituotteista oli merkittävästi vähentynyt. Lisäksi energia-aineenvaihdunnan keskeiset haarat 
olivat muuttuneet. IOSCA-hermosoluissa sitruunahappokierron välituotteet olivat huvenneet, kun taas 
keskipitkiä ja pitkiä rasvahappoja oli kertynyt soluihin. Lisääntyneet rasvahapposynteesin välituotteet viittasivat 
potilaiden hermosolujen muokanneen aineenvaihduntaansa lipidien syntetisoimiseen tai kykenemättömyyteen 
hyödyntää jo syntetisoituja rasvahappoja.  
 
Koska potilaiden indusoiduista monikykyisistä kantasoluista erilaistetut hermosolut paljastivat eroja terveisiin 
verrokkeihin verrattuna, niitä voitaisiin tulevaisuudessa hyödyntää hoitovaihtoehtoja tutkiessa. Häiriintynyttä 
nukleotidien synteesiä voitaisiin mahdollisesti helpottaa nukleotidien suplementaatiolla ja energia-
aineenvaihdunnan muutoksiin vaikuttaa ruokavalion kautta. 
 
Avainsanat mitokondriotauti, aivosairaus, solumalli, hermosolu, IOSCA, aineenvaihdunta 
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1 Introduction
Mitochondrial diseases can be caused either by mutations in nuclear encoded or mitochondrial DNA
eventually disrupting mitochondrial function. They are the most common inherited metabolic diseases,
usually manifesting in tissues and organs that require most energy, such as the nervous system, muscle,
liver and heart. However, age of onset varies from infancy to old age and practically any tissue of the body
can be affected. Also the inheritance pattern can be any: maternally inherited, autosomal dominant,
recessive or X-linked. Mutations can also occur de novo during embryogenesis. Currently therapy
focuses on relieving symptoms and no curative treatments are available. Because of the heterogeneity of
mitochondrial diseases, making diagnoses can be difficult. It is mainly based on biochemical analyses,
magnetic resonance imaging, tissue biopsy samples and increasingly, genetic testing. (Nunnari and
Suomalainen, 2012)
Impaired maintenance of mitochondrial DNA can lead to mitochondrial DNA (mtDNA) depletion
or deletions, and is a major cause of mitochondrial diseases. Because neurons critically depend on
mitochondrial function due to their extremely high energy demand and special morphology, mitochondrial
dysfunction often leads to neurodegeneration. Mitochondria are mainly known for generating adenosine
triphosphate (ATP), the energy currency used by all cell types. Besides being cellular powerhouses,
mitochondria take part in many important processes, such as biosynthetic pathways, Ca2+-signaling,
cell cycle control and apoptosis. Therefore, mitochondrial dysfunction does not necessarily lead to an
inadequate amount of ATP, but rather it can initiate an integrated stress response, alter metabolic
pathways or cause an imbalance in redox balance. (Suomalainen and Battersby, 2017)
Human diseases are often studied using animals as a model. However, they do not always recapitulate
the disease phenotype and require extensive resources in time and money. Therefore, cellular models
can be used as an alternative and additional method. When a disease affects the nervous system, a
tissue biopsy is not desirable or even applicable. Induced pluripotent stem (iPS) cells are obtained
from differentiated cells, such as skin fibroblasts, by genetically engineering them back to a stem cell
state where they hold the capacity to differentiate into all three germ layers (Takahashi and Yamanaka,
2006). Therefore, neurons derived from patient iPS cells make an excellent tool for studying molecular
mechanisms of neuropathological diseases in vitro.
The aim of this thesis was to study an early onset severely disabling mitochondrial ataxia, infantile
onset spinocerebellar ataxia (IOSCA), using patient iPS cell-derived neurons and neural cells as a model.
IOSCA is a recessively inherited disease which belongs to the Finnish disease heritage with a carrier
frequency of more than 1:230 (Hakonen et al., 2008). IOSCA is caused by a homozygous mutation
(Y508C) in the mitochondrial helicase Twinkle (Nikali et al., 2005). Symptoms start to manifest during
infancy and include progressive spinocerebellar ataxia, hearing loss, epilepsy and hepatopathy (Koskinen
et al., 1994). IOSCA patients develop mitochondrial DNA depletion in brain and liver (Hakonen et al.,
2008), and the disease has been shown to alter major metabolic pathways through one-carbon metabolism
(Nikkanen et al., 2016). Currently there is no curative treatment available and identification of the
underlying molecular mechanisms is essential to enable intervention.
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2 Mitochondria
2.1 Dynamic networks of bacterial descendants
Mitochondria are the organelles that convert energy from carbohydrates, fatty acids and proteins to
adenosine triphosphate (ATP), the energy currency of all cells. Mitochondria originate from an alpha-
proteobacterium that once was engulfed by an early eukaryote (Lane and Martin, 2010). All human cells
except mature red blood cells contain mitochondria, but the number varies in different tissues depending
on energy requirements. Mitochondria consist of an outer membrane facing the cytosol and a highly
folded inner membrane separating two compartments: the intermembrane space and the mitochondrial
matrix (figure 1). Both membranes are phospholipid bilayers embedded with proteins. The outer mem-
brane covers the entire organelle and is numerous with pores that ions and small molecules, even proteins,
are able to pass. The inner membrane is much more impermeable and loaded with proteins involved in
energy metabolism. It is arranged into highly folded cristae which increases the surface area greatly.
Figure 1: A transmission electron microscope image of mitochondria in iPS cell-derived neurons. M =
mitochondrion, G = golgi apparatus, ER = endoplasmic reticulum. Imaging by Christopher Jackson.
Mitochondria constantly participate in fission and fusion events and form a highly dynamic network
that is integrated to other cellular compartments such as the endoplasmic reticulum (ER) (figure 1).
Mitochondria move along microtubules and alter their network structure to meet the demands of the
changing cellular environment. Mitochondrial dynamics allows the exchange of mitochondrial contents
and lipids throughout the mitochondrial population. Fusion alleviates stress as contents of partially
damaged mitochondria are mixed. Fission creates new mitochondria and enables the isolation of damaged
ones. Several proteins control mitochondrial dynamics. Two proteins are involved in the fusion of outer
mitochondrial membranes: Mitofusin 1 and 2, and one in the fusion of inner membranes: OPA1 (Optic
atrophy 1) (Song et al., 2009). Mitochondrial fission occurs at sites where mitochondria contact ER
tubules, and DRP1 (Dynamin-related protein 1) is recruited to perform fission (Smirnova et al., 2001;
Friedman et al., 2011). (Chen and Chan, 2009)
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The unique origin of mitochondria and the fact that they participate in so many vital processes
make mitochondria particularly vulnerable to accumulating damage throughout life. Therefore, specific
mitochondrial quality control systems have evolved to ensure mitochondrial integrity. First of all, mi-
tochondria are loaded with proteases and chaperones that protect them from accumulating misfolded
proteins (Rugarli and Langer, 2012). Mitochondrial quality is managed also on an organellar level.
During stress, mitochondria hyperfuse to increase ATP production and avoid autophagy (Rugarli and
Langer, 2012). In case mitochondrial fusion is impaired due to mitochondrial dysfunction, continuous
fission events fragment the mitochondrial network. Mitochondrial fragmentation signals for mitochon-
drial turnover and fragmented mitochondria are removed through selective autophagy, or mitophagy. In
the process of mitophagy, mitochondria are engulfed into autophagosome marker microtubule associated
protein 1 light chain 3 (LC3) coated vesicles and trafficked to the lysosome for degradation (figure 2)
(Kim et al., 2007).
Figure 2: Mitophagy is the controlled process of identifying, isolating and trafficking mitochondria to
the lysosome for degradation in autophagosome marker microtubule associated protein 1 light chain 3
(LC3) coated vesicles.
2.2 Own genome with a distinct translation and maintenance machinery
Mitochondria contain their own DNA which encodes for 13 of the total 93 protein subunits of the
respiratory chain and ATP synthase, as well as 22 transfer and 2 ribosomal RNAs involved in their
translation (figure 3). Mitochondrial DNA is almost exclusively maternally inherited in all mammals.
Mitochondria contain multiple copies of the double-stranded circular 16 569 base pair long mtDNA
molecule (Anderson et al., 1981), with the exact number commonly being 2-10, at least in cultured cells
(Iborra et al., 2004). The outer strand contains most mitochondrial genes and is referred to as the heavy
strand (H-strand). The inner strand is named the light strand (L-strand). The displacement loop, or
D-loop, is a major control region for mtDNA expression as it contains major promoters and the origin
of replication for the leading strand. Physically it is a short strand corresponding to the L-strand and
displacing the H-strand.
Mitochondrial DNA is located within the mitochondrial matrix and organized into protein containing
nucleoids that are attached to the inner mitochondrial membrane. Mitochondrial DNA and its translation
machinery still present features of the prokaryotic origin. The genetic code of four codons differs from
eukaryotic genomes and mitochondrial ribosomal RNAs resemble more bacterial than eukaryotic ones.
The mitochondrial genome is very compact as it does not contain introns. It has decreased in size
throughout evolution due to gene transfer to the nucleus (Timmis et al., 2004). Therefore, mitochondria
are under control of two distinct genomes. The vast majority of mitochondrial proteins are encoded in
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the nucleus, translated in the cytosol and imported to mitochondria through specialized transporters
(Neupert and Herrmann, 2007).
Figure 3: Map of the mitochondrial genome. The outer strand contains most mitochondrial genes and is
called the heavy strand, whereas the inner strand is referred to as the light strand. D-loop (displacement-
loop) = a major control region for mitochondrial DNA expression. OH and OL = origin of replication
for each strand.
The exact mechanism of mtDNA replication is still under some debate. The strand-displacement
model suggests that mtDNA is replicated unidirectionally starting from the D-loop, until the origin of
replication for the light strand is reached, and then the light strand replicated to the opposite direction
(Clayton, 1982). Another model proposes that mtDNA is replicated bidirectionally in a strand-coupled
manner, starting from a wider region downstream of the origin of replication for the heavy strand (Holt
et al., 2000). Finally, the RITOLS (RNA incorporated throughout the lagging strand) model predicts
unidirectional synthesis but while DNA synthesis progresses on the leading strand, RNA is incorporated
on the lagging strand, and as DNA is synthesized on the lagging strand, RNA is replaced by DNA (Yang
et al., 2002; Yasukawa et al., 2006). However, there is evidence of different replication models occurring
in different tissues and also between different species (Pohjoismaki et al., 2009). Unlike nuclear DNA
replication, mtDNA replication is not linked to cell cycle but instead mitochondrial fission, which is
regulated by ER-mitochondria contacts, at least in cultured cells (Clayton, 1982; Lewis et al., 2016).
The entire mitochondrial DNA maintenance machinery is encoded in the nucleus. Mitochondrial
DNA is replicated by mitochondrial DNA polymerase gamma (PolG), the replicative helicase Twinkle,
mitochondrial single-stranded DNA binding protein (SSBP1), mitochondrial RNA polymerase, mito-
chondrial transcription factor A (TFAM) and some additional mtDNA processing enzymes (figure 4).
The minimal replisome consists of PolG, Twinkle and SSBP1 (Korhonen et al., 2004).
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Figure 4: The minimal mitochondrial replisome consists of polymerase gamma (PolG), the helicase
Twinkle and single-stranded DNA binding protein (SSBP). Mitochondrial transcription factor A (TFAM)
is one regulator of mtDNA copy number.
TFAM is a transcription factor that bends and unwinds mitochondrial DNA, and is necessary for
mtDNA expression (Fisher et al., 1992; Shi et al., 2012a). TFAM has been shown to also act as a regu-
lator of mtDNA copy number (Ekstrand et al., 2004). It is the most abundant protein in nucleoids and
therefore a critical factor in packaging mtDNA. PolG is the main mitochondrial DNA polymerase and
vital for mtDNA replication. It is a heterotrimeric protein which consists of one catalytic subunit (PolG)
and two regulatory subunits (PolG2) (Yakubovskaya et al., 2006). Mitochondrial DNA is replicated with
high fidelity due to the exonuclease proofreading activity of PolG (Longley et al., 1998). Twinkle is the
mitochondrial helicase that has a hexameric ring-like structure homologous to the phage T7 primase/he-
licase (Spelbrink et al., 2001). Twinkle has lost its primase activity but still unwinds mitochondrial DNA
for replication, and probably acts as a licensing factor, since overexpression of Twinkle increases mtDNA
copy number (Tyynismaa et al., 2004). However, the exact mechanism of mtDNA copy number control
is unknown.
2.3 Mitochondria is the powerhouse of the cell
Mitochondria are key players in energy metabolism which is reflected by the fact that an increase in
the demand of ATP leads to increased mitochondrial mass (Hoppeler and Fluck, 2003). Mitochondria
generate ATP through three main pathways: oxidative phosphorylation (OXPHOS), the tricarboxylic
acid cycle (TCA cycle) and fatty acid oxidation (FAO), which all operate in the mitochondrial matrix.
The tricarboxylic acid cycle is an important driver of cellular respiration, harvesting energy from acetyl
coenzyme A (acetyl-CoA) to the reducing equivalents NADH (nicotinamide adenine dinucleotide) and
FADH2 (flavin adenine dinucleotide). Fatty acid oxidation breaks down fatty acids and generates acetyl-
CoA, which enters the TCA cycle, and also NADH and FADH2. The electron carriers pass their electrons
to the mitochondrial electron transport chain (ETC), which generates most ATP in cellular respiration
through oxidative phosphorylation. Mitochondrial energy metabolism is summarized in figure 5.
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Figure 5: Mitochondria generate ATP through three main pathways: fatty acid oxidation (FAO), the
tricarboxylic acid cycle (TCA cycle) and oxidative phosphorylation (OXPHOS).
Mitochondrial activity is sensed through NAD+/NADH and AMP/ATP ratios, as well as acetyl-CoA
levels. Sensors include transcription factors, hormones, cofactors, nuclear receptors and kinases (Nunnari
and Suomalainen, 2012). An increased AMP/ATP ratio or ADP concentration, indicating insufficient
mitochondrial function, is sensed by AMP-activated protein kinase (AMPK) (Carling et al., 1987; Hardie
et al., 2006). AMPK activation leads to upregulation of catabolic processes, OXPHOS and autophagy,
whereas cell growth and proliferation are downregulated (Carling et al., 2011). Another key metabolic
sensor is Sirtuin 1, which responds to an increase in NAD+-levels. Together with AMPK it regulates
mitochondrial biogenesis and ATP production via the transcription cofactor peroxisome proliferator-
activated receptor gamma coactivator 1 alpha (Canto et al., 2010; Wu et al., 1999).
2.3.1 The tricarboxylic acid cycle
Carbohydrates, fats and amino acids are initially processed to acetyl coenzyme A which then enters
the TCA cycle that operates in the mitochondrial matrix. Acetyl-CoA can be derived from glycolysis,
pyruvate oxidation or fatty acid oxidation. The TCA cycle can also be fed by some amino acids. The
TCA cycle consists of eight enzyme-catalyzed reactions that while oxidizing acetyl-CoA, reduce NAD+
to NADH, and FAD to FADH2. NADH and FADH2 act as electron carriers and transfer their electrons
to the electron transport chain; NADH to complex I and FADH2 to complex II.
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2.3.2 Fatty acid oxidation
Fatty acids are a major source of energy that are required especially during fasting and long term
exercise. Short- and medium-chain fatty acids are able to passively diffuse cell membranes but long-
chain fatty acids need to be transported by sodium dependent fatty acid transporters (Hirsch et al.,
1998). Once inside cells, fatty acids are activated by converting them to fatty acyl-CoA esters by fatty
acyl-CoA-synthetases. Fatty acyl-CoA esters can serve as substrates for cholesterol, phospholipids and
triacylglycerol, or be transported to mitochondria for FAO by the carnitine shuttle.
Fatty acid oxidation occurs as a series of dehydrogenation, hydration, a second dehydrogenation and
thiolysis reactions. The end product of each cycle is a fatty acyl-CoA ester shortened by two carbons,
an acetyl-CoA molecule and two electrons that proceed to OXPHOS. The shortened fatty acyl-CoA
ester enters the cycle repeatedly until only two acetyl-CoAs remain. In mammals fatty acid oxidation
requires also peroxisomes. Long- and medium-chain fatty acids can be oxidized by both mitochondria
and peroxisomes, however, long-chain dicarboxylic, very long-chain monocarboxylic and branched-chain
fatty acids are only accepted by peroxisomes.
2.3.3 Oxidative phosphorylation
Most energy in mammalian cells is produced in the aerobic process of oxidative phosphorylation by the
mitochondrial electron transport chain. The ETC consists of four protein complexes located on the in-
ner mitochondrial membrane: complex I (NADH dehydrogenase), complex II (succinate dehydrogenase),
complex III (coenzyme Q10-cytochrome c oxidoreductase) and complex IV (cytochrome c oxidase), and
ATP synthase, which is often referred to as complex V. CI accepts electrons from NADH yielding NAD+.
CII accepts electrons from FADH2 yielding FAD, and operates also in the TCA cycle converting suc-
cinate to fumarate. Both CI and CII donate the electrons to the small mobile coenzyme Q10 (CoQ10
or ubiquinone) which is reduced to ubiquinol. NAD+ and FAD are recycled back to the TCA cycle.
Ubiquinol travels through the membrane carrying the electrons to complex III that transfers them to
cytochrome c. In the last step, CIV donates the electrons from cytochrome c to molecular oxygen thereby
forming water. Importantly, CI, CIII and CIV pump protons from the mitochondrial matrix to the inter-
membrane space while transferring electrons to each other, and thus create an electrochemical potential
across the membrane (Mitchell, 1961). As protons move back to the mitochondrial matrix along the
electrochemical gradient through ATP synthase, ADP is phosphorylated to ATP. The respiratory chain
complexes form combinations of supercomplexes or respirasomes that are physically and functionally
linked, which enhances the transfer of electrons (Schagger and Pfeiffer, 2000). (Saraste, 1999) Figure 6
gives an overview of the process of oxidative phosphorylation.
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Figure 6: The mitochondrial electron transport chain consists of four protein complexes that shuttle
electrons to one and other and finally donate them to oxygen. Simultaneously CI, III and IV pump
protons to the intermembrane space from the mitochondrial matrix. As protons travel back to the
matrix through ATP synthase, or CV, ADP is phosphorylated to ATP.
2.4 Mitochondria are chemical factories and signaling centers
Although mitochondria are most known for generating ATP, they have numerous other crucial functions.
Mitochondria regulate pools of metabolites, amino acids and cofactors for several regulatory enzymes
(Suomalainen and Battersby, 2017). They also have a central role in synthesizing heme for oxygen delivery
and iron-sulfur clusters for metalloproteins including those of the respiratory chain (Lill and Kispal, 2000).
Mitochondria are closely connected to the endoplasmic reticulum and the ER-mitochondrial junction is
important for calcium homeostasis and signaling (Csordas et al., 2010). Mitochondrial intermediate
metabolites can act as epigenetic regulators in the nucleus, and control cell cycle and apoptosis (Lu and
Thompson, 2012). A functional electron transport chain maintains an electrochemical gradient across
the mitochondrial inner membrane which is important for more than just ATP production. It is needed
for example for protein import (Dudek et al., 2013) and changes in the membrane potential signal of
mitochondrial dysfunction. Mitochondrial depolarization causes degradation of OPA1 and mitofusins
and therefore mitochondrial fragmentation (Rugarli and Langer, 2012).
Mitochondria are also at the core of the folate cycle which is tightly linked to a larger set of phys-
iological processes known as one-carbon metabolism. The folate cycle produces formyl-methionine for
mitochondrial translation initiation and folates that activate and transfer one-carbon units to purine
synthesis, methyl cycle and transsulfuration in the cytoplasm (Tibbetts and Appling, 2010). One-carbon
metabolism supports amino acid homeostasis of glycine, serine and methionine, epigenetic maintenance
as well as redox defense (Ducker and Rabinowitz, 2017). Mitochondrial 5,10-methylene-tetrahydrofolate
dehydrogenase produces NADH when active, and therefore connects one-carbon metabolism to the res-
piratory state of the cell. Interestingly, mitochondrial DNA replication defects have been shown to
remodel one-carbon metabolism (Nikkanen et al., 2016). A graphical overview of one-carbon metabolism
is presented in figure 7.
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Figure 7: Mitochondria are at the core of one-carbon metabolism, which supports a group of important
cytoplasmic processes: purine synthesis, methyl cycle and transsulfuration. PHGDG = phosphoglycerate
dehydrogenase, PSAT1 = phosphoserine aminotransferase 1, 3PG = 3-phosphoglycerate, 3-POHPyr =
3-phosphohydroxypuryvate, PSer = phosphoserine, THF = tetrahydrofolate, MTHFD = methylene-
tetrahydrofolate dehydrogenase, fMet = formyl methionine.
2.5 Neurons are demanding habitats for mitochondria
The brain requires 20% of the total oxygen supply of the body (Kann and Kovacs, 2007). Neurons alone
require immense amounts of ATP for maintaining ion gradients across their membranes and for neuro-
transmission. They are also highly polarized post-mitotic cells with far-reaching extensions, which causes
special requirements regarding for example membrane maintenance and axonal transport. Mitochondria
need to form a highly mobile network in neurons and rely on anterograde and retrograde transport to
areas of high energy demand, such as synapses and growth cones seeking for synaptic targets. Therefore,
neurons critically depend on reliable mitochondrial function.
Mitochondrial fusion and axonal transport machineries are tightly connected. Mutations in OPA1
cause optic atrophy (Delettre et al., 2000) and mutations in Mitofusin 2 a peripheral neuropathy:
Charcot-Marie-Tooth type 2A (Zuchner et al., 2004). Therefore, it is clear that neurons require in-
tact mitochondrial dynamics. Changes in mitochondrial morphology also disrupt interactions with the
endoplasmic reticulum and therefore mitochondrial Ca2+-homeostasis. A tight regulation of calcium
buffering in synapses is crucial for neuronal firing and an excessive influx of calcium can initiate apopto-
sis (Giorgi et al., 2008). Mitochondria also supply building blocks for neurotransmitters and are involved
in lipid synthesis which is crucial for neuronal function (Kann and Kovacs, 2007).
In neurons, mitochondria need to be transported from the cell body to neurites that can be even
over a meter long. With a velocity ranging from 0.1μm/sec to 2μm/sec (Ligon and Steward, 2000), it
could take two weeks for a mitochondrion to reach the synapse after leaving from the soma. Therefore,
their half life in neurons is longer than that of mitochondria in other tissues. In rat brain their half life
has been found to exceed four weeks (Menzies and Gold, 1971), so in human brain their half life could
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reach months. Most nuclear encoded mitochondrial proteins are loaded to mitochondria in the cell body
before they travel to their destination. Thus, besides being vulnerable of accumulating damage, neuronal
mitochondria face a risk of being outdated when arriving to their destination. Also autophagosomes,
although being formed in axons, have to travel a long distance to the cell body to fuse with lysosomes
(Rugarli and Langer, 2012). It is not known, how this process is affected by mitochondrial dysfunction.
3 Consequences of mitochondrial dysfunction
3.1 Mitochondrial DNA depletion syndromes
Mitochondrial DNA depletion syndromes (MDS) are caused by loss of mtDNA. Mitochondrial DNA
maintenance can be challenged due to an impaired mtDNA replication machinery or an insufficient
amount of necessary building blocks: dNTPs (deoxyribonucleoside triphosphates). Mitochondrial DNA
depletion syndromes typically manifest at infancy with high tissue specificity leading to impaired OX-
PHOS in affected tissues and organs. Energy metabolism is mainly glycolytic during fetal life so even
severe respiratory deficiencies may not prevent normal development. After birth, the role of oxidative
energy metabolism increases, as does the amount of mtDNA and expression of its proteins targeted to
the respiratory chain. MDS are clinically heterogeneous but usually they can be categorized into either
myopathic, hepatocerebral, encephalomyopathic or neurogastrointestinal forms. Mitochondrial DNA
depletion syndromes often lead to early death. (Suomalainen and Isohanni, 2010)
The genetic background of mitochondrial DNA depletion syndromes is heterogeneous. Most MDS
causing mutations affect proteins involved in dNTP synthesis. The cytosolic nucleotide pools are closely
linked to mitochondrial ones and in post-mitotic tissues they mainly serve mtDNA replication. Myopathic
MDS is caused by mutations in TK2 (thymidine kinase 2) which operates inside mitochondria in the
pyrimidine nucleoside salvage pathway. Encephalomyopathic forms are caused by mutations in RRM2B
(ribonucleoside-diphosphate reductase subunit M2), SUCLA2 (succinate-CoA ligase ADP-forming beta
subunit) and SUCLG1 (mitochondrial succinate-CoA ligase ADP/GDP-forming subunit alpha). RRM2B
encodes the small subunit of the cytosolic ribonucleotide reductase, which catalyzes the reduction of
ribonucleoside diphosphates into their corresponding deoxyribonucleoside diphosphates. Succinyl-CoA
ligase is a TCA cycle enzyme catalyzing the reversible conversion of succinyl-CoA to succinate, and ADP
to ATP or GDP to GTP, depending on its beta-subunit. Hepatocerebral forms of MDS are caused by
mutations in dGUOK (deoxyguanosine kinase) which is involved in the mitochondrial purine nucleoside
salvage pathway, MPV17 (mitochondrial inner membrane protein 17) with an unknown role in mtDNA
maintenance, and PolG and Twinkle which belong to the mtDNA replication fork. Mutations in TYMP
(thymidine phosphorylase) cause a mitochondrial neurogastrointestinal encephalopathy. TYMP encodes
thymidine phosphorylase that catalyzes the conversion of thymidine to thymine and deoxyuridine to
uracil in the cytosol. Figure 8 gives an overview of nucleotide synthesis and illustrates proteins that have
been identified to cause mitochondrial DNA depletion syndromes. (Suomalainen and Isohanni, 2010)
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Figure 8: Mitochondrial DNA depletion syndromes are caused by mutations impairing nucleotide syn-
thesis (TK2 = thymidine kinase 2, dGUOK = deoxyguanosine kinase, RNR = ribonucleotide reduc-
tase, SUCL = succinyl-CoA ligase, TYMP = thymidine phosphorylase) or mtDNA replication (PolG =
polymerase gamma, Twinkle). Also mutations in mitochondrial inner membrane protein 17 (MPV17),
with an unknown function, cause MDS. NDPK = nucleoside diphosphate kinase, NMPK = nucleoside
monophosphate kinase, TK1 = thymidine kinase 1, dNTP = deoxynucleotide triphosphate, dNDP =
deoxynucleotide diphosphate, dNMP = deoxynucleotide monophosphate.
Puzzling is that even the most severe forms of MDS do not cause developmental abnormalities even
though fetal life is highly proliferative and requires active mtDNA replication. This could be explained
by maternal contribution to the fetal dNTP pools or a high expression of defective proteins during
fetal life. Apart from MDS caused by mutations in SUCLA2, the manifestation of mitochondrial DNA
depletion syndromes is different from Leigh syndrome, which is caused by deficiencies in one or more
of the respiratory chain protein complexes and their assembly factors. PolG related phenotypes include
mitochondrial recessive ataxia syndrome (MIRAS) which closely resembles IOSCA, Alpers syndrome and
sensory ataxia, neuropathy, dysarthria, ophthalmoplegia (SANDO) syndrome. In addition to IOSCA,
mutations in Twinkle have been associated with autosomal dominant progressive ophthalmoplegia. Only
PolG and Twinkle defects cause intractable epilepsy and both are also associated with liver failure
induced by the epilepsy drug valproate. (El-Hattab and Scaglia, 2013; Suomalainen and Isohanni, 2010)
3.1.1 Infantile onset spinocerebellar ataxia
Infantile onset spinocerebellar ataxia is a recessively inherited mitochondrial ataxia belonging to Finnish
disease heritage with a carrier frequency of more than 1:230 (Hakonen et al., 2008). IOSCA is caused
by a homozygous (Y508C) mutation in the mitochondrial helicase Twinkle (Nikali et al., 2005). The
mutation has been also found as compound heterozygous with the mutation A318T, in patients mani-
festing an Alpers-like hepatocerebral disease (Hakonen et al., 2007). IOSCA patients develop normally
until the age of 10 to 18 months when first symptoms of ataxia, dysarthria, hypotonia, hearing loss and
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ophthalmoplegia start to present. Spinocerebellar degeneration is progressive; neuropathological features
include atrophy of the cerebellum, brain stem and spinal cord, as well as sensory axonal neuropathy.
Based on examinations on the sural nerve, myelinated fibers degenerate progressively and large myeli-
nated fibers are completely lost. Patients require a wheelchair or a walker by adolescence and hearing loss
progresses into deafness. A difficult-to-treat epilepsy starts usually in teenage and often develops into
a life threatening status epilepticus. Additional clinical characteristics include migraine, optic atrophy,
female hypergonadotropic hypogonadism and liver involvement. (Koskinen et al., 1994) Currently the
underlying molecular mechanisms of the disease are unknown and there is no curative treatment.
The Y508C mutation is located in the helicase domain of Twinkle. Homology modeling of the mutant
protein has revealed that the mutation uncouples nucleoside triphosphate (NTP) hydrolysis from the
binding and translocation of single-stranded DNA resulting in independent NTP hydrolysis (Nikkanen
et al., 2016). IOSCA patients develop mtDNA depletion in large neurons and liver, but no mtDNA
deletions. The IOSCA mutation also creates a conserved heme-binding motif but it does not bind heme
covalently. The disease affects especially large neurons of the frontal cortex and cerebellum, and in line
with mtDNA depletion, respiratory chain complex I, and more subtly also complex IV, are reduced. Post
mortem analysis of the brain has also revealed a loss of Purkinje cells in the cerebellum as well as gliosis
and atrophy of the dentate nucleus. (Hakonen et al., 2008)
Standard laboratory metabolic screenings, including cerebrospinal fluid (CSF) lactate, have been
normal in IOSCA patients (Koskinen et al., 1994). Patients with compound heterozygous mutations
(Y508C and A318T) however, have had mildly elevated serum and CSF lactate, and occasionally elevated
liver transaminases and alpha-fetoprotein (Hakonen et al., 2007). However, a 100 metabolite analysis of
IOSCA patient blood revealed remodeling of one-carbon metabolism (Nikkanen et al., 2016). The main
end products of transsulfuration were decreased and also purine metabolism was affected as adenosine
was decreased almost 8-fold in IOSCA patient blood compared to controls (Nikkanen et al., 2016). Also
guanidinoacetate/creatine metabolism was disturbed (Nikkanen et al., 2016). An IOSCA patient and a
heat map of 25 most significantly altered metabolites in IOSCA patient blood is shown in figure 9.
12
Figure 9: An IOSCA patient and 25 most significantly changed metabolites in IOSCA patient blood.
Figure modified from Nikkanen et al. (2016).
A mouse model has been generated for IOSCA and it, like patients, had decreased mtDNA content in
liver but unlike patients, not in other tissues. The IOSCA mouse brain recapitulated the human disease
phenotype with neurodegeneration affecting especially Purkinje cells and large pyramidal neurons of the
CA1 hippocampal region. In addition, IOSCA mouse muscle had low dNTP pools and amino acids and
their blood shared disease specific metabolite patterns with patients. The mice, however, did not show
motor or sensory defects. (Nikkanen et al., 2016)
3.2 Activation of an integrated stress response and remodeling of metabolic
pathways
Mitochondria are under control of two separate genomes and must therefore actively communicate with
the nucleus to achieve coordinated functions. Communication pathways include those from the nucleus
to mitochondria and vice versa. These anterograde and retrograde signals are collectively called mitonu-
clear communication. In times of stress, depending on the specific signal and its severity, mitonuclear
communication can develop into an integrated stress response (ISR). The ISR can originate also from
other cellular compartments such as the endoplasmic reticulum, and instead of having a cell autonomous
response have effects on the whole organism (Quiros et al., 2016).
The integrated stress response begins with phosphorylation of eukaryotic translation initiation factor
2 α (Dalton et al., 2012). It promotes expression of specific stress response genes like ATF4 (activating
transcription factor 4) which in turn induces various stress proteins such as ATF3 (activating transcrip-
tion factor 3) and TRIB3 (tribbles homologue 3) (Quiros et al., 2016). Activation of the stress response
shuts down cytosolic translation and tries to restore normal cellular function.
An integrated mitochondrial stress response (ISRmt), specific to mitochondrial dysfunction and not
overlapping with stresses originating from other cellular compartments, has been found to be induced
in patients, mice and cell lines with mtDNA maintenance and translation defects (Suomalainen and
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Battersby, 2017). Defects in oxidative phosphorylation and mtDNA can send retrograde signals to the
nucleus via reactive oxygen species (ROS), decreased ATP levels or Ca2+ release from mitochondria
due to impaired membrane potential. The ISRmt involves upregulation of genes that have an amino
acid response element (AARE) in their regulatory region (Tyynismaa et al., 2010). AAREs are bound
by activating transcription factors that have been associated with the unfolded protein response. How-
ever, unfolded proteins are rarely found in mammalian mitochondria, and in patients the mitochondrial
unfolded protein response is only subtly induced (Suomalainen and Battersby, 2017). Instead, in post-
mitotic tissues, the proteins from AARE transcripts regulate lipid and glucose metabolism and the
anabolic one-carbon cycle (figure 10) (Nikkanen et al., 2016; Bao et al., 2016).
Figure 10: mtDNA expression defects activate an integrated stress response which is driven by activating
transcription factors ATF3-5 that recognize amino acid response elements (AARE) in their target genes.
ATFs are at least partially controlled by mechanistic target of rapamycin complex 1 (mTORC1). Ac-
tivation of mitochondrial bifunctional methylene-tetrahydrofolate dehydrogenase 2 (MTHFD2) impacts
nucleotide, phospholipid and glutathione synthesis as well as methylation reactions. The ISRmt can
also have consequences on systemic metabolism through secreted fibroblast growth factor 21 (FGF21).
Figure modified from Suomalainen and Battersby (2017).
One-carbon metabolism is supported by the folate cycle which operates partially inside mitochondria.
The folate cycle is regulated by the redox-sensitive enzyme methylene-tetrahydrofolate dehydrogenase 2
(MTHFD2) which has an amino acid response element in its promoter (Tyynismaa et al., 2010). The
stress induced folate cycle provides cells with nucleotides, the antioxidant glutathione, NADPH and phos-
pholipids for membrane maintenance. In mitochondrial myopathy, caused by dominant mutations in the
mitochondrial helicase Twinkle, MTHFD2 is chronically induced which remodels one-carbon metabolism
and causes imbalanced dNTP pools (Nikkanen et al., 2016). Also studies on HEK-cells have shown that
mtDNA depletion activates serine biosynthesis and transsulfuration through ATF4 (Bao et al., 2016).
However, these pathways have not been well studied in the nervous system.
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3.3 Impaired redox signaling
All life involves a constant flux of energy which requires complex redox reactions at the cellular level.
Redox reactions include all reactions involving the transfer of electrons between chemical substances;
oxidation referring to the loss of electrons and reduction to the gain of electrons. Nicotinamide adenine
dinucleotide, NAD+ in its oxidized and NADH in its reduced form, and nicotinamide adenine dinucleotide
phosphate (NADP), NADP+ when oxidized and NADPH when reduced, are crucial redox agents in all
living cells. NADPH is retained mostly in the reduced form to promote reductive anabolic reactions,
whereas NAD is mainly maintained in the oxidized form for catabolic reactions (Klingerberg and Buecher,
1960). The separation allows thermodynamically incompatible reactions to occur simultaneously. A
correct balance of reducing and oxidizing reactions is crucial for several cellular functions.
The mitochondrial NAD+/NADH ratio is in a more reduced state than the cytosolic one, probably to
keep glycolysis occurring in the cytosol and OXPHOS in mitochondria (Cracan et al., 2017). Mitochon-
drial membranes are not permeable to NADH or NADPH. However, oxidation of NADH in mitochondria
results in the same event in the cytosol, at least in cancer cells (Titov et al., 2016). Data from cancer
cells shows also that mitochondrial, but not cytosolic, NAD+/NADH and NADP+/NADPH pools are
connected (Cracan et al., 2017). Both reduction potentials rely on the activity of major metabolic
pathways and shuttle systems. The NADP+/NADPH ratio is mainly determined by the pentose phos-
phate pathway, one-carbon metabolism, cytosolic malic enzyme and isocitrate dehydrogenase whereas
the NAD+/NADH ratio is primarily determined by the TCA cycle, OXPHOS and glycolysis.
The importance of tight regulation of both ratios is an emerging theme as an impaired redox-balance
has been connected to diseases like cancer, diabetes and also normal aging (Cracan et al., 2017). The
NAD+/NADH ratio signals to multiple pathways. For example in order to keep peroxisomal beta-
oxidation ongoing, NADH must be reoxidized to NAD+ and this process might rely on redox-shuttles
involving mitochondria (Fransen et al., 2017). Also mitochondrial beta-oxidation requires NAD+ in
the step converting 3-hydroxyacyl-CoA to 3-ketoacyl-CoA. Interestingly, both peroxisomal diseases, and
those of mitochondrial beta-oxidation, often lead to neurodegeneration with liver involvement (Fransen
et al., 2017; Nsiah-Sefaa and McKenzie, 2016).
Reactive oxygen species are highly reactive molecules that can damage major cellular components.
ROS are derived from the reduction of oxygen either with a single electron, creating superoxide, two
electrons, creating hydrogen peroxide, or three electrons, creating the hydroxyl radical. Respiratory chain
complexes I and III are the primary sources of ROS in mitochondria and mitochondria the major sources
of ROS in cells (Murphy, 2009; Muller et al., 2004; Turrens, 2003). A dysfunctional respiratory chain is
more prone to produce ROS. The primary mitochondrial ROS is superoxide (O−2 ) which is converted to
hydrogen peroxide (H2O2) by superoxide dismutases, both in mitochondria and in the cytosol. Hydrogen
peroxide can be reduced to water or partially reduced to form the hydroxyl radical (OH), which is one
of the strongest oxidants in nature (Turrens, 2003). ROS can damage major components of cells: lipids,
nucleic acids and proteins, and alter cellular survival and differentiation (Hamanaka and Chandel, 2010).
The brain, and especially neurons, are vulnerable to oxidative stress because they have a low antiox-
idant defense capacity, high oxidative metabolism rate and a high concentration of unsaturated fatty
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acids which are prone to lipid peroxidation (Belanger et al., 2011). Several neurodegenerative diseases
have been associated with oxidative stress. About a tenth of familial amyotrophic lateral sclerosis (ALS)
cases have been linked to mutations in the superoxide dismutase coding gene SOD1 (Valentine and Hart,
2003), and a knockdown of SOD2 to cause similar histopathology as seen in Leber hereditary optic neu-
ropathy (Qi et al., 2003). Furthermore, postmortem brain biopsies from Alzheimer’s, Parkinson’s and
ALS patients show ROS damage in affected brain areas (Niedzielska et al., 2016).
4 Modeling neurodegeneration on a dish
4.1 Induced pluripotent stem cells
Stem cells are undifferentiated cells with unlimited proliferation capacity and ability of giving rise to
differentiated cells. Pluripotent cells can give rise to all three germ layers and all cell types except
placental cells and cells of the fetal membrane. The three germ layers include the endoderm, ectoderm
and mesoderm. Endodermal cells give rise to epithelial cells of the gastrointestinal system, lungs and
airways, ectodermal cells to neural cells and skin cells, and mesodermal cells to cells of the connective
tissue, muscles and blood. Pluripotent embryonic stem cells (ES cells) can be isolated from an early-stage
embryo. Autologous sources of stem cells are bone marrow, adipose tissue and blood. Most adult stem
cells are multipotent. Multipotent stem cells are capable of differentiating into more than one cell type
but their differentiation capacity is more limited than that of pluripotent stem cells. (Alberts et al.,
2002)
A method for reprogramming already differentiated adult skin fibroblasts to pluripotent stem cells was
established in 2006 (Takahashi and Yamanaka, 2006). Retroviral transduction of the four transcription
factors Oct3/4, Sox2, c-Myc, and Klf4 reverted fibroblasts to a stem cell state where they expressed
ES cell markers and morphologically resembled ES cells. Furthermore, the reprogrammed cells were
capable of differentiating into all three germ layers after subcutaneous transplantation to nude mice.
These genetically engineered pluripotent cells were named induced pluripotent stem cells. iPS cells
were expected to revolutionize the field of stem cell therapy but risks of tumorigenesis have not yet
been overcome. However, iPS cells are currently valuable tools for disease modeling and drug discovery.
Harvesting disease associated tissues or cells is not always possible and collecting stem cells is considered
invasive. Instead, patient fibroblasts can be isolated from a simple skin biopsy, genetically engineered to
a stem cell state and then differentiated to relevant cell types.
4.2 Neuronal differentiation in vivo and in vitro
During early development, the ectodermal germ layer gives rise to the neuroectoderm, which transforms
into the neural plate, neural groove and neural tube, and all mammalian neurons are ultimately derived
from neuroepithelial cells of the neural plate and neural tube (Tortora and Derrickson, 2012). The human
cortex accounts for three quarters of the brain and is its integrative and executive center. Approximately
80% of cortical neurons are excitatory glutamatergic neurons and the remaining 20% inhibitory GABAer-
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gic neurons (Florio and Huttner, 2014). In vivo, glutamatergic neurons differentiate from cortical stem
and progenitor cells, whereas GABAergic neurons develop outside the cortex and migrate in during de-
velopment (Wonders and Anderson, 2006). Human cortical neurogenesis spans probably almost a 100
day period (Caviness et al., 1995). In a diseased brain, the cortex is the site of epilepsy and a subject of
neurodegeneration. The human neural stem and progenitor population consists of three major groups
of cells: apical, subapical and basal progenitors, which are grouped based on the location where they
undergo mitosis (figure 11) (Florio and Huttner, 2014).
Figure 11: Apical, subapical and basal progenitors are the three main groups of neural progenitors
giving rise to all cortical neurons. Neuroepithelial cells dominate the apical region and are therefore not
depicted in the figure. Figure adapted from Florio and Huttner (2014).
Neuronal differentiation has been accomplished in vitro using several different methods. Neural
cells can be generated by reprogramming somatic cells first to stem cells, and then directing their
differentiation towards neural cells. Also direct reprogramming, or trans-differentiation, of somatic cells
directly to neural cells has been succesfull with different combinations of transcription factors (Ring et al.,
2012; Yoo et al., 2011; Vierbuchen et al., 2010). The ultimate goal is to generate functional neuronal
networks in vitro that resemble disease relevant networks found in vivo. Stem cells differentiating in
vitro undergo similar stages seen in vivo. Human pluripotent stem cells, such as iPS cells, resemble
the inner cell mass of the early-stage embryo. Differentiation into neuroepithelial cells and rosette-type
neural progenitors in vitro mirror the formation of the neural plate and neural tube, respectively, in vivo.
Rosette-type progenitors give rise to radial glial like neural progenitors, and further to neurons and glial
cells. (Mertens et al., 2016)
One commonly used method for neuronal differentiation is a suspension culture that does not drive
differentiation towards any specific neuronal subtype. In this method, pluripotent cells are collected on
a low attachment culture plate and cultured as free floating spheres, neurospheres, for several weeks in a
defined culture medium, after which they are plated as small aggregates on a surface that supports their
terminal differentiation and maturation. With this method, human embryonic stem cells spontaneously
form electrically active neuronal networks (Lappalainen et al., 2010; Heikkila et al., 2009).
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Another common method utilizes small molecule inhibitors to direct pluripotent cells towards the
neuronal lineage. Neural progenitors have been successfully generated by blocking two signaling pathways
that utilize SMADs as transcription factors: TGF-β signaling and bone morphogenic protein (BMP)
signaling (Chambers et al., 2009). The method is referred to as dual SMAD inhibition. A model for the
underlying mechanisms proposes that TGF-β inhibition destabilizes TGF/activin- and Nanog-mediated
pluripotency and suppresses mesodermal fates, whereas BMP inhibition promotes neuralization of early
ectoderms. Dual SMAD inhibition has driven over 80 percent of human ES and iPS cells to express the
early neural progenitor marker Pax6 (Paired box 6) in 11 days (Chambers et al., 2009). Furthermore,
combining dual SMAD inhibition with retinoid signaling has increased the efficiency of neural induction,
as over 95 % of cells have been driven to express neural progenitor markers in 15 days (Shi et al., 2012b).
A high initial cell density favors the generation of cells of the central nervous system, and a low density
of cells of the neural crest (Chambers et al., 2009). Both human embryonic and iPS cells form cortical
rosettes that are polarized similarly to the cortical neuroepithelium, and give rise to a mixed population
of apical and basal progenitors (Shi et al., 2012b). After allowing the progenitors to mature, they start to
express glutamatergic but not GABAergic neuronal markers (Shi et al., 2012b). GABAergic neurons can
be obtained by ventralizing the progenitors by inhibiting hedgehog signaling (Shi et al., 2012b). Neural
progenitors obtained by dual SMAD inhibition can be further differentiated towards the desired neuronal
subtype. Terminal differentiation to midbrain dopaminergic and spinal motorneurons (Chambers et al.,
2009) as well as electrically active cortical neurons (Shi et al., 2012b) has been succesfull. The proposed
model of mechanisms underlying neuronal differentiation by dual SMAD inhibition is presented in figure
12.
Figure 12: Model of mechanisms underlying neuronal differentiation by dual SMAD inhibition proposed
by Chambers et al. (2009). A. A high initial cell density favors the formation of Pax6 positive cells
of the central nervous system (CNS), which can give rise to rosette type neural stem cells (NSCs) and
patternable neuronal subtypes. B. A low initial cell density gives rise to both cells of the CNS and
PNS (peripheral nervous system). Solid arrows indicate demonstrated cell fates whereas dashed arrows
indicate proposed fates. Figure modified from Chambers et al. (2009).
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4.3 Cellular models of neuronal diseases
Diseases of the nervous system are ones of the most difficult to study because taking a biopsy of the
manifesting cell types, neuronal cells, is typically not possible. However, many patient-derived iPS cell
lines have been successfully created and differentiated to disease relevant neuronal cell types. Successful
attempts include neuronal cultures from Alzheimer’s disease patients (Israel et al., 2012), motor neurons
from ALS patients (Dimos et al., 2008) but also neurons from patients with rarer diseases such as
spinocerebellar ataxia type 2 (Xia et al., 2013). Not only has it been possible to obtain the cell types
of interest, but they have shown disease related changes such as susceptibility to huntingtin aggregate
formation in Huntington’s disease patient-derived neurons (Jeon et al., 2012) and accumulation of Lewy
bodies in iPS cell-derived dopaminergic neurons of a Parkinson’s disease patient (Sanchez-Danes et al.,
2012).
Patient-derived iPS cells and therefore also neuronal cells differentiated from them, carry the same
genetic variants that cause the disease. Furthermore, the disease causing mutations sit on the exactly
same genetic background as they do in patients. Modeling a disease with patient-derived cells has also
challenges. The magnitude of differences between iPS cell lines generated from the same individual have
not been fully addressed yet. Therefore, it is not known if the seemingly random differences between
iPS cell lines can hide those caused by changes due to the disease causing genetic variants. Ideally, each
patient cell line would have an isogenic control, meaning the same cell line with the disease causing
variant corrected by gene editing, resulting in two cell lines with identical nuclear genomes, except for
the presence or absence of the mutation.
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5 Aims of the study
The aims of this thesis were to:
1. Obtain IOSCA patient-derived neural cells that would manifest a neuronal phenotype related to the
disease.
2. Analyze molecular and metabolic consequences of the mutant form of Twinkle, to shed light on the
pathogenic cellular and molecular mechanisms underlying symptoms in IOSCA.
6 Materials and methods
6.1 Culture of iPS cells
IPS cells were cultured on Corning Matrigel Matrix (Sigma-Aldrich) coated wells in Essential 8 medium
(Thermo Fisher Scientific) and passaged with 10mM ethylenediaminetetraacetic acid (EDTA).
6.2 Neuronal differentiation
6.2.1 Differentiation as neurospheres - Method 1
For this work, frozen 4-6 week old neurospheres were rapidly thawed, and transferred on ultra-low
attachment well plates (Thermo Fisher Scientific) in neural differentiation medium (NDM) containing
1:1 DMEM/F12:Neurobasal medium supplemented with 2 mM GlutaMAX, 1x B27, 1x N2 and 25 μg/ml
penicillin/streptomycin (All from Gibco Thermo Fisher Scientific), and 20 ng/ml basic fibroblast growth
factor (bFGF) (Sigma-Aldrich). The spheres were manually cut twice each week into smaller spheres
(maximum diameter 500 μm) to expose most cells to the medium and avoid differentiation towards
unwanted cell lineages. Half of the culture medium was changed three times each week. The spheres
were cultured for 3,5 weeks to obtain 7.5-9.5 week old neurospheres. For neuronal differentiation the
spheres were manually cut into small aggregates and plated on human laminin (Sigma-Aldrich) coated
(10 μg/ml for polystyrene and 15 μg/ml for glass coverslips) 12 and 24 well plates in NDM without
bFGF. On day 3 after plating, the medium was changed into Neurobasal medium with 1x B27, 1x
GlutaMAX, 1x CultureOne supplement (Thermo Fisher Scientific), 0.1 mM ascorbic acid and 0.25x
penicillin/streptomycin. The differentiation process is depicted in figure 13.
Figure 13: Neural differentiation as neurospheres.
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6.2.2 Differentiation via dual SMAD inhibition - Method 2
For method 2, iPS cells were cultured until nearly confluent, and then medium was changed to neural
induction medium (NIM) containing 1:1 DMEM/F12:Neurobasal medium, 0.5x N2 supplement, 0.5x
B27 supplement, 0.5x GlutaMAX, 0.25x penicillin/streptomycin, 0.1 mM ascorbic acid (Santa Cruz), 2
μM BMP Inhibitor II and 2 μM TGF-β RI kinase inhibitor VI (both from Merck). Cells were cultured
in NIM for 7-9 days with a daily medium change. Cells were then detached with 50 mM EDTA and
plated on human laminin coated wells in the same medium without dual SMAD inhibition but with 20
ng/ml bFGF, at a cell density of 600 000 cells/cm2. After 2 days bFGF was removed and after 3-5
more days medium changed to terminal differentiation medium containing Neurobasal medium, 1x B27,
1x GlutaMAX, 1x CultureOne supplement, 0.1 mM ascorbic acid and 0.25x penicillin/streptomycin.
Differentiation via dual SMAD inhibition is presented in figure 14.
Figure 14: Neural differentiation by dual SMAD inhibition.
6.3 Immunocytochemistry
For immunocytochemistry, cells were fixed with 4% paraformaldehyde for 15 minutes in room temper-
ature, or with -20◦C acetone for 2 minutes on ice when cells were on glass coverslips. The cells were
washed with phosphate-buffered saline (PBS), permeabilized with 0.1% Triton-X100 (Sigma-Aldrich)
and blocked using 10% horse serum and 1% bovine serum albumin (BSA) in PBS for 45 minutes in room
temperature. Cells were then washed with 1% horse serum, 0.1% Triton-X100 and 1% BSA in PBS and
incubated with the primary antibodies in the same buffer overnight in +4◦C. After three washes with 1%
BSA in PBS, the cells were incubated with the secondary antibodies protected from light for 1 hour in
room temperature. The cells were finally washed twice with PBS and twice with PB, dried and mounted
with Vectashield containing DAPI (4’,6-diamidino-2-phenylindole) (Vector laboratories). All antibodies
and working dilutions used in this work are presented in figure 15.
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Figure 15: Antibodies used in this work.
6.4 Gene expression analyses
Frozen cell pellets were homogenized and total RNA was extracted by pipetting into TRIzol (InVitrogen).
RNA concentration was quantified with Nanodrop and 500 ng of RNA was used to generate cDNA with
Maxima first-strand cDNA synthesis kit (Thermo Fisher Scientific). CDNA was amplified with iQ SYBR
Green Supermix (Biorad) on CFX96 Touch qPCR system (Biorad). Amplification levels of analyzed genes
were normalized to reference housekeeping genes. All primer pairs used in this study are presented in
figure 16. Gene expression data is presented as fold change.
Figure 16: Primers used in this work.
6.5 mtDNA copy number analysis
DNA was extracted from frozen cell pellets with proteinase K digestion, traditional phenol-chloroform
extraction and ethanol precipitation. Relative mtDNA content was analyzed by qPCR using 25 ng of
total DNA as a template, similarly as in chapter 6.4. Amplification levels of the mitochondrial gene
cytochrome B (cytB) and D-loop were normalized to nuclear genes amyloid-beta protein (APP) or beta-
2-microglobulin (B2M), respectively, and are presented as fold change. Primer pairs are presented in
figure 16.
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6.6 Analysis of neuronal morphology and number
Neurons were stained for the neuronal marker MAP2 (microtubule associated protein 2) and all nuclei
counterstained with DAPI. Neurons were detected based on their morphology and MAP2 positivity. The
percentage of neurons was analyzed from ten randomly taken images of each cell line. The morphology of
individual neurons was analyzed from 100 neurons differentiated with M1 and 50 neurons differentiated
with M2, for both the disease and control group. Analysis was performed with Simple Neurite Tracer in
the Fiji software (https://imagej.nih.gov/ij/; version 1.51n).
6.7 Quantification of immunocytochemical stainings
Quantification of fluorescent stainings was done in Fiji software (https://imagej.nih.gov/ij/; version
1.51n) by normalizing the signal intensity of the target to the signal intensity of the neuronal marker
MAP2. For all stainings, at least 150 neurons were analyzed for both the disease and control group.
6.8 Metabolite extraction and analysis
Samples for metabolomics were extracted from two control cell lines and three IOSCA cell lines differ-
entiated as neurospheres, and two control cell lines and four IOSCA cell lines differentiated with the
dual SMAD inhibition method. Four biological replicates were used for each cell line. To extract the
metabolites, medium was removed from cells with an aspirator and wells washed twice with 75 mM
Ammonium Carbonate in water with pH adjusted to 7.4 with acetic acid. Plates were then snap frozen
in liquid nitrogen and stored at -80◦C until metabolite extraction in order to reduce sources of variance.
Metabolite extraction was performed for all samples with the same reagents on the same day. Metabolites
were extracted with two 10 minute incubations with -20◦C 40:40:20 acetonitrile:methanol:water solution
in -20◦C and by scraping the cells after the second incubation. Extracts were centrifuged at 13 000 rpm
for 2 minutes in +4◦C and supernatants collected for untargeted mass spectrometry.
Untargeted mass spectrometry, as well as annotation and curation of the data, were done in ETH
Zurich by Dr. Nicola Zamboni (Williams et al., 2016). Untargeted metabolomics of the iPS cell-derived
neural cells captured 503 metabolites. Of the 503 metabolites, metabolites annotated as drugs, toxins
and non-mammalian metabolites were removed, after which 388 metabolites remained. The data was
obtained as peak intensities for each metabolite, with two technical replicates for each of the four bio-
logical replicates. The technical replicates were averaged and the peak intensity table was uploaded to
MetaboAnalyst 3.0 (Xia and Wishart, 2016). Before statistical analyses and plotting, peak intensities
were normalized by a pooled control sample and log transformed. MetaboAnalyst 3.0 and R were used
for analyzing and plotting the data.
6.9 Statistical methods
Student’s t-test was used for statistical significance analyses. For false positive analyses in metabolomics,
p-values were adjusted based on the Benjamini-Hochberg (BH) procedure. P-values of less than 0.05
were considered as significant. All statistical tests were performed with GraphPad Prism 7.03.
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7 Results and Discussion
7.1 Characterization of iPS cells
Three iPS cell lines (C2-C4) and one ES cell line (C1) were used in this study as controls, and four iPS
cell lines were derived from patients (I1-I4). All iPS cell lines were first characterized in order to confirm
successful reprogramming. All cell lines formed colonies with similar morphology to the embryonic stem
cell line and expressed pluripotency markers Nanog, lin28A, Oct3/4 and SSEA4 comparably to the ES cell
line (figure 17 and figure 18). Based on the morphology of iPS cell colonies and immunocytochemistry,
all iPS cell lines were pluripotent before initiating neuronal differentiation. All control and IOSCA
patient-derived iPS cells were analyzed also for their expression of the reprogramming viral transgenes
Oct4, Sox2, Klf4 and Cmyc. The reprogramming transgenes were successfully silenced in all iPS cell
lines before initiating neuronal differentiation (figure 19).
Figure 17: Representative images of the expression of pluripotency markers lin28A and Nanog in control
and IOSCA induced pluripotent stem (iPS) cell lines and one control embryonic stem (ES) cell line. All
iPS cell lines expressed pluripotency markers and formed colonies with a similar morphology to the ES
cell line C1. C1-C4 = control 1-control 4, I1-I4 = IOSCA 1-IOSCA 4.
Figure 18: Representative images of the expression of pluripotency markers Oct3/4 and SSEA4 in control
and IOSCA iPS cell lines and one control ES cell line.
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Figure 19: Relative expression of the viral reprogramming transgenes Oct4, Sox2, Klf4 and Cmyc com-
pared to expression in the control ES cell line. Reprogramming transgenes were successfully silenced
before neural induction in all used iPS cell lines.
7.2 IOSCA patient iPS cells successfully differentiate into neural precursors
with M2
Neuronal differentiation was initiated on control and IOSCA patient-derived iPS cells and control ES
cells, with the dual SMAD inhibition method, once the cultures were nearly confluent. After eight days
in neural induction medium, all cell lines had grown completely confluent and the size of individual
cells decreased significantly. Three control cell lines and three IOSCA cell lines were analyzed for their
expression of the early neural markers Nestin, Musashi-1 and Pax6 at day eight after neural induction.
When compared to expression levels of corresponding iPS cells, all neural precursors expressed Nestin and
Musashi-1 with an increase of at least a fold change (figure 20). Pax6 is a transcription factor involved
in the development of the brain and spinal cord, and is one of the earliest markers of a transition from
pluripotency towards the neural lineage (Zhang et al., 2010). Pax6 showed a substantial upregulation in
all cell lines when compared to expression levels in corresponding iPS cells with no differences between
control and IOSCA cell lines (figure 20).
Figure 20: Relative expression of neural precursor markers Pax6, Nestin and Musashi-1 at day eight
after initiating neural induction compared to expression in corresponding induced pluripotent stem cells.
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Three control cell lines and three IOSCA cell lines were analyzed for their expression of Pax6 at day
eight also by immunocytochemistry. Most cells of all analyzed cell lines stained positively for Pax6 and
there were no differences between control and IOSCA cell lines (figure 21). After eight days, all analyzed
cell lines had successfully transitioned towards the desired neural lineage.
Figure 21: Representative images of the expression of the early neural marker Pax6 eight days after initi-
ating neuronal differentiation analyzed by immunocytochemistry. All analyzed cell lines had successfully
transitioned towards the neural lineage at day eight.
7.3 Characterization of neural cultures
7.3.1 IOSCA neurons show signs of impaired maturation with M1 after two weeks
Neuronal differentiation of iPS cells was performed as described in chapter 6.2.1 on two control cell lines
and three IOSCA cell lines, and neurons fixed after two weeks of maturation. The percentage of neurons
was significantly lower in IOSCA neural cultures than in controls (figure 22). Contaminating cell types
included astrocytes or astrocytic precursors, based on their morphology and modest expression of MAP2,
which can be expressed by some astrocytic subtypes, even though being primarily a neuronal marker
(Dehmelt and Halpain, 2005). Most contaminating cells, however, were large flat cells without any clear
identity and which could be identified easily also under a light microscope. The smaller percentage of
neurons in neural cultures obtained from IOSCA cell lines could suggest impaired neuronal differentiation.
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Figure 22: IOSCA patient-derived neural cultures had significantly less neurons than controls, based on
their morphology and MAP2 positivity. A. Representative images of control and IOSCA neural cultures
after two weeks of maturation. Neurons were stained for the neuronal marker microtubule associated
protein 2 (MAP2) and nuclei counter stained with DAPI. B. Quantification of the percentage of neurons
from ten randomly taken images per cell line. Error bars indicate standard deviation and data points
the percentage of neurons in one image. M1 = differentiation method 1. ****p<0.0001
Also the morphology of individual neurons was analyzed, and interestingly, IOSCA-patient derived
neurons were morphologically distinct when compared to controls. While most control neurons were
bipolar with far reaching neurites, the patient-derived neurons had a higher number of neurites but
they were significantly shorter (figure 22 insets and figure 23). Also the number of branching points
in individual neurites was analyzed but no difference was found (figure 23). A reduced percentage of
neurons and their distinct morphology could indicate accelerated but impaired neuronal differentiation
or maturation in IOSCA. Morphological abnormalities, although different from the results of this work,
have been found also in the hippocampal CA1 region of pyramidal neurons in IOSCA mice, as they have
been shown to have decreased neurite density, as well as disorganized dendritic trees (Nikkanen et al.,
2016).
Figure 23: IOSCA patient-derived neurons were significantly more polar but their neurites were shorter
than in controls, which could suggest that their differentiation or maturation is impaired. Error bars
indicate standard deviation and data points the morphology of individual neurons. ****p<0.0001
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7.3.2 Neuronal yield is low from cryopreserved neural precursors even after four weeks
with M2
Neuronal differentiation of iPS and control ES cells was performed as described in chapter 6.2.2 on four
control cell lines and four IOSCA cell lines. Metabolomics-, DNA- and RNA-samples were collected at
two weeks after plating neural precursors on laminin-coated wells. Samples that were used for immuno-
cytochemistry were obtained from neural precursors that were cryo-preserved, thawed and plated on
laminin-coated glass coverslips to continue with terminal differentiation. However, some cell lines, not
depending on their origin, were reluctant to attach and continue proliferation after freezing and thawing.
Poly-L-ornithine was added as a second coating material to enhance attachment. Because proliferation
and cell growth was extremely slow, cells were kept in culture for four weeks before fixing them for
immunocytochemistry. Even at that time point, only two control and two IOSCA cell lines had enough
neurons to be analyzed. There were no differences in differentiation capacity between these control and
IOSCA cell lines (figure 24). Terminal differentiation of cryopreserved neural precursors yielded a very
impure neural culture with a massive amount of contaminating cells. Most of the contaminating cells
were ambiguous and distinct of the flat cells and astrocytic precursors obtained from neurospheres.
Figure 24: Cryopreserved neural precursors yielded only a low percentage of neurons even at week 4,
with no differences between control and IOSCA cell lines when using differentiation method 2. A. Rep-
resentative images of control and IOSCA patient-derived neural cultures after four weeks of maturation
with cryopreserved neural precursors obtained with the dual SMAD inhibition method. Cells were fixed
at week 4 due to slow recovery after freezing. Neurons were stained for MAP2 and nuclei counter stained
with DAPI. B. Quantification of the percentage of neurons from ten randomly taken images per cell line.
Error bars indicate standard deviation and data points the percentage of neurons in one image. M2 =
differentiation method 2.
Also for M2, the morphology of individual neurons was analyzed. However, no difference was found
in the morphology of control and patient-derived neurons at the analyzed time point of four weeks (figure
25). Unfortunately neuronal morphology was analyzed at two different time points for the two different
differentiation methods. It could be that even though the recovery of neuronal precursors differentiated
with M2 seemed extremely slow after cryopreservation, the recovered cells had a longer maturation time,
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and therefore the controls had enough time to reach the same maturation stage as IOSCA neurons.
Therefore, it could be that IOSCA neurons mature faster than wild type neurons in vitro, which is seen
at two weeks. Furthermore, impaired neuronal differentiation or maturation could be related to the
pathology of IOSCA. However, a major differentiation defect would be likely to cause developmental and
structural brain defects in patients, which has not been found. In addition, being seen only with one
of the differentiation methods, the analysis should be repeated by analyzing different time points using
only one differentiation method.
Figure 25: Morphology of individual control and IOSCA patient-derived neurons from cryopreserved
neural precursors was similar at the analyzed time point of four weeks, when using M2. Error bars
indicate standard deviation and data points the morphology of individual neurons.
7.4 IOSCA neural cells do not develop mtDNA depletion in two weeks
Mitochondrial DNA copy number has been shown to be decreased in IOSCA patient brain and liver
(Hakonen et al., 2008), and therefore relative mtDNA content was analyzed from the patient-derived
neural cells. Because of limited sample size, it was possible to be analyzed only from neural cells
obtained with the dual SMAD inhibition differentiation method. However, mtDNA depletion was not
significant at two weeks (figure 26). This could be due to a too short culture time for detectable mtDNA
depletion to develop, or a masking effect of contaminating cell types, which comprised more than half of
the cell population.
Figure 26: Relative mtDNA content was not significantly altered in IOSCA patient-derived neural cells
after two weeks of maturation, when compared to controls. Relative mtDNA content was analyzed by
two different primer pairs: B2M and mitochondrial D-loop, as well as APP and mitochondrial cytB.
Data is presented as median and error bars indicate interquartile range.
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7.5 Mitochondrial network is reduced in IOSCA neurons
Because complex I and to a lesser extent also complex IV have been shown to be decreased in IOSCA
patient brain (Hakonen et al., 2008), they were analyzed by immunocytochemistry in control and patient-
derived neurons. Also CII was analyzed as it is the only one of the respiratory chain complexes that
is entirely nuclear encoded. Similarly to patients, CI and CIV were significantly decreased but CII was
unaltered in IOSCA patient-derived neurons (figure 27).
Figure 27: Respiratory chain complexes I and IV were decreased but complex II was unchanged in
IOSCA patient-derived neurons when compared to controls. A. Representative images of MAP2- and
CI-staining in control and IOSCA patient-derived neurons differentiated with M1. B. Quantification of
CI/MAP2 signal intensity in control and patient-derived neurons. C. Representative images of MAP2-
and CII-staining in control and patient-derived neurons. D. Quantification of CII/MAP2 signal intensity
in control and patient-derived neurons. E. Representative images of MAP2- and CIV-staining in control
and patient-derived neurons. F. Quantification of CIV/MAP2 signal intensity in control and patient-
derived neurons. Data points represent RC complex signal intensity/MAP2 signal intensity in individual
neurons. Error bars indicate standard deviation. *p<0.05
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Also the total mitochondrial network was visualized and analyzed by staining for mitochondrial
import receptor subunit TOM20 (translocase of outer membrane 20). Surprisingly, IOSCA neurons had
significantly less mitochondria, when compared to controls, in neurons differentiated with both methods
(figure 28). Patient-derived neurons seemed to have normal mitochondrial networks in the soma but
many of their neurites were almost completely empty of mitochondria. CII being unaltered could be
explained by a compensatory effect, if patient-derived neurons had induced nuclear-encoded CII, which
is a common finding in respiratory chain deficiencies (Hamalainen et al., 2013). However, CII staining
was relatively faint in both control and patient neurons and, therefore, this aspect of the experimentation
requires further replication.
Figure 28: IOSCA-patient derived neurons had reduced mitochondrial networks especially in their neu-
rites, regardless of the differentiation method. A. Representative images of control and IOSCA-patient
derived neurons, differentiated with M1, stained for MAP2 and mitochondria stained for translocase of
outer membrane 20 (TOM20) after two weeks of maturation. B. Quantification of TOM20/MAP2 signal
intensity in neurons differentiated with M1. Data points represent individual neurons. C. Representa-
tive images of MAP2 and TOM20-staining in neurons differentiated with M2, with a maturation time of
four weeks after cryopreservation. D. Quantification of TOM20/MAP2 signal intensity in neurons dif-
ferentiated with M2. Data points represent individual neurons. Error bars indicate standard deviation.
**p<0.01, ****p<0.0001
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To investigate whether the loss of mitochondria was due to excessive mitophagy, autophagosomes
were stained for autophagosome membrane marker LC3B and mitochondria for TOM20. Neurons were
identified based on their morphology. Immunocytochemistry did not show more colocalization of LC3B
and TOM20 in IOSCA patient-derived neurons than in controls. However, if mitophagy occurs mainly
around the soma, before mitochondria reach neurites, it would be difficult to detect the event with this
method. Therefore, it would be interesting to analyze turnover of mitochondria in live cells, utilizing for
example mito-QC (McWilliams et al., 2016).
Figure 29: Colocalization of TOM20 with LC3 autophagosome membrane marker was not increased in
IOSCA patient-derived neurons.
7.6 The ISRmt, one-carbon metabolism and serine biosynthesis are not ac-
tivated in IOSCA neural cells
The mitochondrial integrated stress response has been shown to be activated in patients and disease mod-
els with mtDNA maintenance and translation defects, especially in the heart and muscle (Suomalainen
and Battersby, 2017). Therefore, expression of its activating transcription factors 3-5 and TRIB3, were
analyzed. None of them, however, were significantly upregulated in patient-derived neural cells when
compared to controls (figure 30). The integrated stress response might be tissue or mutation-specific
and therefore not relevant for neural cells carrying the IOSCA mutation.
Figure 30: Activating transcription factors 3-5 and TRIB3 of the mitochondrial integrated stress response
were not upregulated in IOSCA patient-derived neural cells when compared to controls. Data presented
as median and error bars indicate interquartile range.
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Dominant mutations of Twinkle, causing mitochondrial myopathy and modeled by the deletor mouse,
cause a transcriptional starvation response in muscle (Tyynismaa et al., 2010). This includes the in-
duction of one-carbon metabolism and serine biosynthesis, serine being the primary 1C donor to the
mitochondrial folate cycle (Nikkanen et al., 2016). Therefore the expression of one of the key enzymes of
the 1C cycle, MTHFD2, and two of serine biosynthesis, PHGDH and PSAT1, were analyzed by qPCR.
However, no significant changes were seen in the expression of any of the analyzed enzymes (figure 31).
The strong induction of serine biosynthesis and one-carbon metabolism in deletor muscle could be tissue
or mutation specific and, therefore not relevant to IOSCA neural cells.
Figure 31: Expression of MTHFD2, a key enzyme in the mitochondrial folate cycle, and PSAT1 and
PHGDG, key enzymes in serine biosynthesis, were not upregulated in IOSCA patient-derived neural
cells. Data presented as median and error bars indicate interquartile range.
7.7 Major metabolic pathways are altered in IOSCA neural cells
Metabolic profiling of control and IOSCA neural cells was performed by untargeted mass spectrome-
try. Untargeted metabolomics revealed genotype-specific metabolic profiles, independent of the used
neuronal differentiation method as seen in figure 32 A. Metabolites most contributing to the variance
between IOSCA and control groups are presented in figure 32 B. The metabolite contributing most
to the variance of the two groups was N-acetyl-L-aspartic acid (NAA, Acetyl-Asp), which was lower
in IOSCA patient-derived neural cells when compared to controls. NAA is one of the most abundant
metabolites in the brain, and synthesized in neurons from aspartate and acetyl-CoA. It is a precursor for
the neurotransmitter N-acetylaspartylglutamic acid and it plays a role in energy metabolism in neuronal
mitochondria. The reason for NAA being the top hit could be simply because IOSCA neural cultures
had a smaller percentage of neurons. However, decreased NAA could also reflect neuronal and especially
axonal damage.
IOSCA neural cells had an increased amount of two ceramides, C16-ceramide and C18-ceramide,
which both are strong signals for apoptosis. Ceramides can be produced by hydrolysis of sphingomyelin
or by de novo synthesis from serine and palmitate. Sphingomyelin is a key plasma membrane component
which can be hydrolysed by either neutral or acidic sphingomyelinase, of which the neutral sphingomyeli-
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nase is sensitive to oxidative stress. Abnormal sphingolipid metabolism has been seen in ALS patients
and mice, whose motor neurons were hypothesized to degenerate due to oxidative stress induced ac-
cumulation of long-chain ceramides and cholesterol esters (Cutler et al., 2002). Notable is also that
glutathione, the end product of the transsulfuration pathway, was low in IOSCA neurons, as was AMP,
an intermediate in purine synthesis, and a precursor of ATP. Low glutathione and disturbed purine
synthesis have been found also in patient blood (Nikkanen et al., 2016). Glutathione is an important
antioxidant in the brain and therefore, the amount of reactive oxygen species in patient-derived neural
cells would be interesting to analyze. Finally, the TCA cycle intermediate isocitrate was low, suggesting
a disturbed TCA cycle in patient-derived neural cells.
Figure 32: A. Partial least squares discriminant analysis (PLS-DA) showed genotype-specific clustering
of control and IOSCA groups, independent of the neuronal differentiation method. B. Highest ranked
metabolites based on variable importance in projection (VIP score) for the PLS-DA. Acetyl-Asp =
N-acetyl-L-aspartic acid, Cer = ceramide, AMP = adenosine monophosphate, BisP = bisphosphate.
To get an overview of the data, most significantly changed metabolites were visualized on a volcano
plot, which is presented in figure 33. Three purine synthesis intermediates, deoxyadenosine diphos-
phate (dADP), inosine and uridine monophosphate (UMP) were among most significantly decreased
metabolites, again highlighting impaired purine synthesis. Most significantly increased metabolites were
decenedioic acid and sebacic acid, which have been found in high concentrations in the urine of patients
with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency (Tserng et al., 1990). Medium-chain
acyl-CoA dehydrogenase is the enzyme involved in the first step of oxidation of medium-chain fatty
acids. MCAD deficiency manifests in infancy as hypoglycemia, vomiting, hepatopathy, encephalopathy,
seizures and coma (Touma and Charpentier, 1992), symptoms of which hepatopathy, encephalopathy and
seizures are shared with IOSCA. Therefore, there is a possibility of some common underlying disease
mechanisms.
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There has been evidence of a FAO complex having a physical contact with ETC supercomplexes
(Wang et al., 2010), and loss of MCAD has been shown to reduce the levels of respiratory chain complexes
I, III and IV, as well as the OXPHOS supercomplex, and increase oxidative stress (Lim et al., 2018).
Therefore, it would be interesting if similarly an unstable electron transport chain could destabilize
FAO enzymes, and lead to the accumulation of medium- and long-chain fatty acids. However, neural
mitochondria use fatty acids as fuel only during early development after which they shift to glucose
(Erecinska et al., 2004). It is generally accepted that brain tissue has a poor capacity for fatty acid
oxidation due to low enzyme activity and slow translocation of long-chain fatty-acid CoA esters across
the inner mitochondrial membrane (Yang et al., 1987).
Figure 33: Most decreased metabolites in IOSCA patient-derived neural cells included nucleotide syn-
thesis intermediates deoxyadenosine diphosphate (dADP), inosine and uridine monophosphate (UMP).
Two most significantly increased metabolites were medium-chain fatty acids decenedioic acid and sebacic
acid. Blue dots indicate decreased and red dots increased metabolites with BH adjusted p-value<0.05
and absolute log2(FC)>0.5, labeled dots have BH adjusted p-value<0.001.
Thirty most altered metabolites in IOSCA patient-derived neural cells were visualized on a heatmap
which is presented in figure 34. The heatmap was generated using euclidean distance as distance measure
and Ward’s method as the clustering algorithm. Neural cells derived from patients and controls showed
genotype specific metabolic fingerprints. Nucleotide, especially purine synthesis, intermediates formed
a prominent group of decreased metabolites, whereas most metabolites with increased concentration in
the patient-derived neural cells were medium- and long-chain fatty acids.
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Figure 34: Thirty most significantly increased and decreased metabolites in IOSCA patient-derived
neural cells when compared to controls. Purine synthesis intermediates formed a prominent group of
decreased metabolites whereas most metabolites with increased concentration were fatty acids. Columns
represent individual samples. The heatmap was generated using euclidean distance as distance measure
and Ward’s method as the clustering algorithm.
Reduced nucleotide synthesis intermediates included dADP, UMP, AMP, GMP, inosine and hypo-
xanthine. Twinkle has been proposed to hydrolyze dNTPs independent of mtDNA replication, and dNTP
pools have been shown to be depleted in IOSCA mouse muscle (Nikkanen et al., 2016). Continuous
hydrolysis of dNTPs by mutated Twinkle generates dNDPs and inorganic phosphate which is itself a
signaling molecule. Nucleotide synthesis could be increased in IOSCA neurons, in order to replenish
dNTP pools, which could exhaust the cells from nucleotide synthesis intermediates. Of one-carbon
metabolism, also the end product of the transsulfuration pathway, glutathione, was reduced. Changes
in one-carbon metabolism are summarized in figure 35.
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Figure 35: Graphical overview of changes in one-carbon metabolism in IOSCA patient-derived neural
cells. Several intermediates of purine synthesis, as well as glutathione, the end product of the transsul-
furation pathway, were decreased in IOSCA patient-derived neural cells. P-values adjusted for multiple
testing of less than 0.05 were considered significant.
Both de novo and salvage pathway of nucleotide synthesis require 5-phosphoribosyl-α-1-pyrophosphate
(PRPP), which is also the rate-limiting substrate for both pathways (Becker and Kim, 1987). Also the
precursor of PRPP, ribose-5-phosphate, which is produced in the pentose phosphate pathway, can limit
nucleotide synthesis (Pilz et al., 1984). The rate limiting enzyme in the oxidative branch of pentose
phosphate pathway is mainly regulated by the NADP+/NADPH ratio. There is increasing evidence of
the fundamental role of NAD and NADP as regulators of energy metabolism, mitochondrial function,
calcium homeostasis and redox metabolism (Ying, 2008). Their balance and ratio with corresponding
reduced forms would therefore be critical to be analyzed also in IOSCA neural cells.
Several of the increased metabolites in IOSCA patient-derived neural cells were intermediates of
fatty acid synthesis, such as 3-oxodecanoic acid and 3-oxohexadecanoic acid (figure 34). Fatty acids
are synthesized from acetyl-CoA and NADPH on a dimeric fatty acid synthase in the cytosol via the
successive addition of two carbons on the initial acetyl moiety. The end product is a 16-carbon palmitic
acid which can be further modified or elongated. Fatty acids are mainly synthesized in liver, adipose
tissue and lactating mammary glands in humans under normal conditions. However, neurons have
been shown to activate fatty acid synthesis from glutamine and glutamate under hypoxia (Brose et al.,
2014). One regulator of fatty acid metabolism is modulation of acetyl-CoA carboxylase activity. It is
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allosterically activated by citrate and glutamate, and reversibly inactivated through phosphorylation by
AMPK (Munday, 2002; Boone et al., 2000; Vagelos et al., 1963). The hypoxic neurons were hypothesized
to induce fatty acid synthesis through acetyl-CoA carboxylase activity via stimulation of phosphatase by
glutamate, and fatty acid synthesis to be an alternative mechanism to utilize hydrogen and end products
of glycolysis, while minimizing apoptotic effects of lactate accumulation.
Three TCA cycle intermediates, (iso)citrate, malate and fumarate were decreased suggesting also
the TCA cycle to be affected in IOSCA patient-derived neural cells. Noteworthy is that the unstable
intermediate oxalosuccinic acid was slightly induced (FC 1.38). Also glutamine, which can be metabolized
to α-ketoglutarate and fed into the TCA cycle, was decreased. Increased glutaminolysis would provide
the cells with NADPH for lipid and nucleotide synthesis. However, lactate was found in similar levels
compared to controls, revealing that glycolysis was not induced in IOSCA patient-derived neural cells.
Analogously, lactate has not been found to be elevated in homozygous IOSCA patients’ cerebrospinal
fluid (Koskinen et al., 1994).
The accumulation of long- and medium-chain fatty acids and the decrease in TCA cycle intermediates
suggested that the patient-derived neural cells had either channeled their metabolism towards fatty acid
synthesis or their inability to utilize already synthesized fatty acids. Therefore, it would be interesting
to analyze metabolic flux. Because IOSCA patient-derived neurons had shorter neurites than controls, it
could also be that the accumulation of fatty acids was partly due to reduced neurite outgrowth without
changes in fatty acid synthesis. Changes in the TCA cycle and fatty acid metabolism are summarized
in figure 36. Despite all the changes in major metabolic pathways, ATP was well within control range
(figure 37), highlighting that the lack of energy is not key in all mitochondrial diseases.
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Figure 36: Graphical overview of changes in energy metabolism in IOSCA patient-derived neural cells.
Several intermediates of the citric acid cycle were decreased, whereas many intermediates of fatty acid
synthesis were increased, in IOSCA patient-derived neural cells. However, there were also signs of
impaired fatty acid oxidation as the patient-derived neural cells showed accumulation of some medium-
chain fatty acids that have been associated with medium-chain acyl-CoA dehydrogenase deficiency. P-
values adjusted for multiple testing of less than 0.05 were considered significant.
Figure 37: Even though major pathways related to energy metabolism were altered in IOSCA neural
cells, ATP levels were comparable to control cells. Data presented as median and interquartile range
with normalized values.
Finally, one hallmark of peroxisomal diseases is the accumulation of phytanic acid, which had accu-
mulated also in IOSCA patient-derived neural cells (figure 34). Peroxisomes and mitochondria function
together in fatty acid oxidation and bile acid synthesis, and peroxisomal diseases manifest in similar ways
as mitochondrial diseases (Fransen et al., 2017). Phytanic acid has been shown to inhibit mitochondrial
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respiratory chain complexes I-III as well as synaptic Na+/K+ ATPase in rat cerebellum, and inhibition
of the pump has been associated with excitotoxicity and epilepsy (Busanello et al., 2013), which is one of
the symptoms in IOSCA. Therefore, it would be interesting to investigate if the function of peroxisomes
is affected in IOSCA neurons.
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8 Conclusions
Mitochondrial DNA depletion syndromes, such as IOSCA, are often severely disabling diseases that
in the worst case lead to early death. Currently therapy is targeted to relieving symptoms and no
curative treatments are available. The aim of this thesis was to increase understanding of the molecular
consequences of impaired mitochondrial DNA replication specifically in neurons. Even though IOSCA
patient-derived neural cells did not develop significant mitochondrial DNA depletion in two weeks, the
cells showed structural, organellar and metabolic abnormalities, demonstrating the power of cellular
models. Findings of this work may be relevant also for other hepatocerebral mtDNA depletion disorders.
Neurons were obtained with both differentiation methods used in this work. However, the integrity
of neuronal differentiation and maturation remains an open question due to inconsistent results with the
two different differentiation methods. It would be interesting to analyze the percentage of neurons and
their morphology at different time points separately with both methods. A clearly reduced mitochondrial
network was replicated in neurons differentiated with both methods. Either mitochondria are unable to
pass a check point when leaving the soma, or they are excessively degraded by mitophagy in patient-
derived neurons. Mitophagy could be further analyzed using mito-QC (McWilliams et al., 2016) to
illuminate mitochondrial turnover in live cells.
Even though the mitochondrial integrated stress response has been shown to be activated in mtDNA
maintenance and translation defects, it was not induced in IOSCA patient-derived neural cells. Also one-
carbon metabolism and serine biosynthesis, which are induced in dominant mutations of Twinkle, were
not activated in IOSCA patient-derived neural cells. Mitochondrial diseases are highly tissue specific
and therefore it is not surprising that different signaling and metabolic pathways are vital for different
cell types.
Untargeted metabolomics revealed remodeling of major metabolic pathways in IOSCA patient-derived
neural cells. At the core of infantile-onset spinocerebellar ataxia is the mutated Twinkle helicase, crucial
for faithful replication of mitochondrial DNA. The drained purine synthesis intermediates could be a cause
of insatiable nucleotide synthesis. Therefore, it would be interesting to see if nucleotide supplementation
would shift the metabolism of patient-derived neurons towards that of control cells. DNMPs have been
already successfully used as therapy for a muscle specific mitochondrial DNA depletion disease caused
by mutations in TK2 (Garone et al., 2014).
Accumulation of medium- and long-chain fatty acids and impairment of the TCA cycle have not been
previously associated with IOSCA, and were therefore somewhat unexpected. The patient-derived neural
cells showed signs of both impaired degradation and increased synthesis of fatty acids and, therefore,
it would be interesting to analyze metabolic flux. The remodeled energy metabolism could be possibly
affected through diet. Despite the remodeling of major metabolic pathways and reduced amount of
mitochondria, ATP levels were normal, underlining that energy, or the lack of it, is not key in all
mitochondrial diseases.
41
References
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K. and Walter, P. (2002), Molecular Biology of
the Cell, 4 edn, Garland Science.
Anderson, S., Bankier, A. T., Barrell, B. G., de Bruijn, M. H., Coulson, A. R., Drouin, J., Eperon, I. C.,
Nierlich, D. P., Roe, B. A., Sanger, F., Schreier, P. H., Smith, A. J., Staden, R. and Young, I. G.
(1981), ‘Sequence and organization of the human mitochondrial genome’, Nature 290(5806), 457–465.
Bao, X. R., Ong, S. E., Goldberger, O., Peng, J., Sharma, R., Thompson, D. A., Vafai, S. B., Cox, A. G.,
Marutani, E., Ichinose, F., Goessling, W., Regev, A., Carr, S. A., Clish, C. B. and Mootha, V. K.
(2016), ‘Mitochondrial dysfunction remodels one-carbon metabolism in human cells’, Elife 5.
Becker, M. A. and Kim, M. (1987), ‘Regulation of purine synthesis de novo in human fibroblasts by
purine nucleotides and phosphoribosylpyrophosphate’, J. Biol. Chem. 262(30), 14531–14537.
Belanger, M., Allaman, I. and Magistretti, P. J. (2011), ‘Brain energy metabolism: focus on astrocyte-
neuron metabolic cooperation’, Cell Metab. 14(6), 724–738.
Boone, A. N., Chan, A., Kulpa, J. E. and Brownsey, R. W. (2000), ‘Bimodal activation of acetyl-CoA
carboxylase by glutamate’, J. Biol. Chem. 275(15), 10819–10825.
Brose, S. A., Marquardt, A. L. and Golovko, M. Y. (2014), ‘Fatty acid biosynthesis from glutamate and
glutamine is specifically induced in neuronal cells under hypoxia’, J. Neurochem. 129(3), 400–412.
Busanello, E. N., Zanatta, A., Tonin, A. M., Viegas, C. M., Vargas, C. R., Leipnitz, G., Ribeiro, C. A.
and Wajner, M. (2013), ‘Marked inhibition of Na+, K(+)- ATPase activity and the respiratory chain
by phytanic acid in cerebellum from young rats: possible underlying mechanisms of cerebellar ataxia
in Refsum disease’, J. Bioenerg. Biomembr. 45(1-2), 137–144.
Canto, C., Jiang, L. Q., Deshmukh, A. S., Mataki, C., Coste, A., Lagouge, M., Zierath, J. R. and Auwerx,
J. (2010), ‘Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in
skeletal muscle’, Cell Metab. 11(3), 213–219.
Carling, D., Mayer, F. V., Sanders, M. J. and Gamblin, S. J. (2011), ‘AMP-activated protein kinase:
nature’s energy sensor’, Nat. Chem. Biol. 7(8), 512–518.
Carling, D., Zammit, V. A. and Hardie, D. G. (1987), ‘A common bicyclic protein kinase cascade inacti-
vates the regulatory enzymes of fatty acid and cholesterol biosynthesis’, FEBS Lett. 223(2), 217–222.
Caviness, V. S., Takahashi, T. and Nowakowski, R. S. (1995), ‘Numbers, time and neocortical neurono-
genesis: a general developmental and evolutionary model’, Trends Neurosci. 18(9), 379–383.
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M. and Studer, L. (2009),
‘Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling’,
Nat. Biotechnol. 27(3), 275–280.
42
Chen, H. and Chan, D. C. (2009), ‘Mitochondrial dynamics–fusion, fission, movement, and mitophagy–in
neurodegenerative diseases’, Hum. Mol. Genet. 18(R2), R169–176.
Clayton, D. A. (1982), ‘Replication of animal mitochondrial DNA’, Cell 28(4), 693–705.
Cracan, V., Titov, D. V., Shen, H., Grabarek, Z. and Mootha, V. K. (2017), ‘A genetically encoded tool
for manipulation of NADP+/NADPH in living cells’, Nat. Chem. Biol. 13(10), 1088–1095.
Csordas, G., Varnai, P., Golenar, T., Roy, S., Purkins, G., Schneider, T. G., Balla, T. and Hajnoczky, G.
(2010), ‘Imaging interorganelle contacts and local calcium dynamics at the ER-mitochondrial interface’,
Mol. Cell 39(1), 121–132.
Cutler, R. G., Pedersen, W. A., Camandola, S., Rothstein, J. D. and Mattson, M. P. (2002), ‘Evidence
that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor
neurons in amyotrophic lateral sclerosis’, Ann. Neurol. 52(4), 448–457.
Dalton, L. E., Healey, E., Irving, J. and Marciniak, S. J. (2012), ‘Phosphoproteins in stress-induced
disease’, Prog Mol Biol Transl Sci 106, 189–221.
Dehmelt, L. and Halpain, S. (2005), ‘The MAP2/Tau family of microtubule-associated proteins’, Genome
Biol. 6(1), 204.
Delettre, C., Lenaers, G., Griffoin, J. M., Gigarel, N., Lorenzo, C., Belenguer, P., Pelloquin, L., Grosge-
orge, J., Turc-Carel, C., Perret, E., Astarie-Dequeker, C., Lasquellec, L., Arnaud, B., Ducommun, B.,
Kaplan, J. and Hamel, C. P. (2000), ‘Nuclear gene OPA1, encoding a mitochondrial dynamin-related
protein, is mutated in dominant optic atrophy’, Nat. Genet. 26(2), 207–210.
Dimos, J. T., Rodolfa, K. T., Niakan, K. K., Weisenthal, L. M., Mitsumoto, H., Chung, W., Croft, G. F.,
Saphier, G., Leibel, R., Goland, R., Wichterle, H., Henderson, C. E. and Eggan, K. (2008), ‘Induced
pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons’,
Science 321(5893), 1218–1221.
Ducker, G. S. and Rabinowitz, J. D. (2017), ‘One-Carbon Metabolism in Health and Disease’, Cell Metab.
25(1), 27–42.
Dudek, J., Rehling, P. and van der Laan, M. (2013), ‘Mitochondrial protein import: common principles
and physiological networks’, Biochim. Biophys. Acta 1833(2), 274–285.
Ekstrand, M. I., Falkenberg, M., Rantanen, A., Park, C. B., Gaspari, M., Hultenby, K., Rustin, P.,
Gustafsson, C. M. and Larsson, N. G. (2004), ‘Mitochondrial transcription factor A regulates mtDNA
copy number in mammals’, Hum. Mol. Genet. 13(9), 935–944.
El-Hattab, A. W. and Scaglia, F. (2013), ‘Mitochondrial DNA depletion syndromes: review and updates
of genetic basis, manifestations, and therapeutic options’, Neurotherapeutics 10(2), 186–198.
Erecinska, M., Cherian, S. and Silver, I. A. (2004), ‘Energy metabolism in mammalian brain during
development’, Prog. Neurobiol. 73(6), 397–445.
43
Fisher, R. P., Lisowsky, T., Parisi, M. A. and Clayton, D. A. (1992), ‘DNA wrapping and bend-
ing by a mitochondrial high mobility group-like transcriptional activator protein’, J. Biol. Chem.
267(5), 3358–3367.
Florio, M. and Huttner, W. B. (2014), ‘Neural progenitors, neurogenesis and the evolution of the neo-
cortex’, Development 141(11), 2182–2194.
Fransen, M., Lismont, C. and Walton, P. (2017), ‘The Peroxisome-Mitochondria Connection: How and
Why?’, Int J Mol Sci 18(6).
Friedman, J. R., Lackner, L. L., West, M., DiBenedetto, J. R., Nunnari, J. and Voeltz, G. K. (2011),
‘ER tubules mark sites of mitochondrial division’, Science 334(6054), 358–362.
Garone, C., Garcia-Diaz, B., Emmanuele, V., Lopez, L. C., Tadesse, S., Akman, H. O., Tanji, K., Quinzii,
C. M. and Hirano, M. (2014), ‘Deoxypyrimidine monophosphate bypass therapy for thymidine kinase
2 deficiency’, EMBO Mol Med 6(8), 1016–1027.
Giorgi, C., Romagnoli, A., Pinton, P. and Rizzuto, R. (2008), ‘Ca2+ signaling, mitochondria and cell
death’, Curr. Mol. Med. 8(2), 119–130.
Hakonen, A. H., Goffart, S., Marjavaara, S., Paetau, A., Cooper, H., Mattila, K., Lampinen, M., Sajan-
tila, A., Lonnqvist, T., Spelbrink, J. N. and Suomalainen, A. (2008), ‘Infantile-onset spinocerebellar
ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal complex I defect and
mtDNA depletion’, Hum. Mol. Genet. 17(23), 3822–3835.
Hakonen, A. H., Isohanni, P., Paetau, A., Herva, R., Suomalainen, A. and Lonnqvist, T. (2007),
‘Recessive Twinkle mutations in early onset encephalopathy with mtDNA depletion’, Brain 130(Pt
11), 3032–3040.
Hamalainen, R. H., Manninen, T., Koivumaki, H., Kislin, M., Otonkoski, T. and Suomalainen, A. (2013),
‘Tissue- and cell-type-specific manifestations of heteroplasmic mtDNA 3243A¿G mutation in human in-
duced pluripotent stem cell-derived disease model’, Proc. Natl. Acad. Sci. U.S.A. 110(38), E3622–3630.
Hamanaka, R. B. and Chandel, N. S. (2010), ‘Mitochondrial reactive oxygen species regulate cellular
signaling and dictate biological outcomes’, Trends Biochem. Sci. 35(9), 505–513.
Hardie, D. G., Hawley, S. A. and Scott, J. W. (2006), ‘AMP-activated protein kinase–development of
the energy sensor concept’, J. Physiol. (Lond.) 574(Pt 1), 7–15.
Heikkila, T. J., Yla-Outinen, L., Tanskanen, J. M., Lappalainen, R. S., Skottman, H., Suuronen, R.,
Mikkonen, J. E., Hyttinen, J. A. and Narkilahti, S. (2009), ‘Human embryonic stem cell-derived
neuronal cells form spontaneously active neuronal networks in vitro’, Exp. Neurol. 218(1), 109–116.
Hirsch, D., Stahl, A. and Lodish, H. F. (1998), ‘A family of fatty acid transporters conserved from
mycobacterium to man’, Proc. Natl. Acad. Sci. U.S.A. 95(15), 8625–8629.
44
Holt, I. J., Lorimer, H. E. and Jacobs, H. T. (2000), ‘Coupled leading- and lagging-strand synthesis of
mammalian mitochondrial DNA’, Cell 100(5), 515–524.
Hoppeler, H. and Fluck, M. (2003), ‘Plasticity of skeletal muscle mitochondria: structure and function’,
Med Sci Sports Exerc 35(1), 95–104.
Iborra, F. J., Kimura, H. and Cook, P. R. (2004), ‘The functional organization of mitochondrial genomes
in human cells’, BMC Biol. 2, 9.
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp,
S., Nazor, K. L., Boscolo, F. S., Carson, C. T., Laurent, L. C., Marsala, M., Gage, F. H., Remes,
A. M., Koo, E. H. and Goldstein, L. S. (2012), ‘Probing sporadic and familial Alzheimer’s disease
using induced pluripotent stem cells’, Nature 482(7384), 216–220.
Jeon, I., Lee, N., Li, J. Y., Park, I. H., Park, K. S., Moon, J., Shim, S. H., Choi, C., Chang, D. J., Kwon,
J., Oh, S. H., Shin, D. A., Kim, H. S., Do, J. T., Lee, D. R., Kim, M., Kang, K. S., Daley, G. Q.,
Brundin, P. and Song, J. (2012), ‘Neuronal properties, in vivo effects, and pathology of a Huntington’s
disease patient-derived induced pluripotent stem cells’, Stem Cells 30(9), 2054–2062.
Kann, O. and Kovacs, R. (2007), ‘Mitochondria and neuronal activity’, Am. J. Physiol., Cell Physiol.
292(2), C641–657.
Kim, I., Rodriguez-Enriquez, S. and Lemasters, J. J. (2007), ‘Selective degradation of mitochondria by
mitophagy’, Arch. Biochem. Biophys. 462(2), 245–253.
Klingerberg, M. and Buecher, T. (1960), ‘Biological oxidations’, Annu. Rev. Biochem. 29, 669–708.
Korhonen, J. A., Pham, X. H., Pellegrini, M. and Falkenberg, M. (2004), ‘Reconstitution of a minimal
mtDNA replisome in vitro’, EMBO J. 23(12), 2423–2429.
Koskinen, T., Santavuori, P., Sainio, K., Lappi, M., Kallio, A. K. and Pihko, H. (1994), ‘Infantile onset
spinocerebellar ataxia with sensory neuropathy: a new inherited disease’, J. Neurol. Sci. 121(1), 50–56.
Lane, N. and Martin, W. (2010), ‘The energetics of genome complexity’, Nature 467(7318), 929–934.
Lappalainen, R. S., Salomaki, M., Yla-Outinen, L., Heikkila, T. J., Hyttinen, J. A., Pihlajamaki, H.,
Suuronen, R., Skottman, H. and Narkilahti, S. (2010), ‘Similarly derived and cultured hESC lines
show variation in their developmental potential towards neuronal cells in long-term culture’, Regen
Med 5(5), 749–762.
Lewis, S. C., Uchiyama, L. F. and Nunnari, J. (2016), ‘ER-mitochondria contacts couple mtDNA syn-
thesis with mitochondrial division in human cells’, Science 353(6296), aaf5549.
Ligon, L. A. and Steward, O. (2000), ‘Movement of mitochondria in the axons and dendrites of cultured
hippocampal neurons’, J. Comp. Neurol. 427(3), 340–350.
45
Lill, R. and Kispal, G. (2000), ‘Maturation of cellular Fe-S proteins: an essential function of mitochon-
dria’, Trends Biochem. Sci. 25(8), 352–356.
Lim, S. C., Tajika, M., Shimura, M., Carey, K. T., Stroud, D. A., Murayama, K., Ohtake, A. and
McKenzie, M. (2018), ‘Loss of the Mitochondrial Fatty Acid B-Oxidation Protein Medium-Chain
Acyl-Coenzyme A Dehydrogenase Disrupts Oxidative Phosphorylation Protein Complex Stability and
Function’, Sci Rep 8(1), 153.
Longley, M. J., Ropp, P. A., Lim, S. E. and Copeland, W. C. (1998), ‘Characterization of the native and
recombinant catalytic subunit of human DNA polymerase gamma: identification of residues critical
for exonuclease activity and dideoxynucleotide sensitivity’, Biochemistry 37(29), 10529–10539.
Lu, C. and Thompson, C. B. (2012), ‘Metabolic regulation of epigenetics’, Cell Metab. 16(1), 9–17.
McWilliams, T. G., Prescott, A. R., Allen, G. F., Tamjar, J., Munson, M. J., Thomson, C., Muqit,
M. M. and Ganley, I. G. (2016), ‘mito-QC illuminates mitophagy and mitochondrial architecture in
vivo’, J. Cell Biol. 214(3), 333–345.
Menzies, R. A. and Gold, P. H. (1971), ‘The turnover of mitochondria in a variety of tissues of young
adult and aged rats’, J. Biol. Chem. 246(8), 2425–2429.
Mertens, J., Marchetto, M. C., Bardy, C. and Gage, F. H. (2016), ‘Evaluating cell reprogramming,
differentiation and conversion technologies in neuroscience’, Nat. Rev. Neurosci. 17(7), 424–437.
Mitchell, P. (1961), ‘Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic
type of mechanism’, Nature 191, 144–148.
Muller, F. L., Liu, Y. and Van Remmen, H. (2004), ‘Complex III releases superoxide to both sides of the
inner mitochondrial membrane’, J. Biol. Chem. 279(47), 49064–49073.
Munday, M. R. (2002), ‘Regulation of mammalian acetyl-CoA carboxylase’, Biochem. Soc. Trans. 30(Pt
6), 1059–1064.
Murphy, M. P. (2009), ‘How mitochondria produce reactive oxygen species’, Biochem. J. 417(1), 1–13.
Neupert, W. and Herrmann, J. M. (2007), ‘Translocation of proteins into mitochondria’, Annu. Rev.
Biochem. 76, 723–749.
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J. and Filip, M. (2016),
‘Oxidative Stress in Neurodegenerative Diseases’, Mol. Neurobiol. 53(6), 4094–4125.
Nikali, K., Suomalainen, A., Saharinen, J., Kuokkanen, M., Spelbrink, J. N., Lonnqvist, T. and Peltonen,
L. (2005), ‘Infantile onset spinocerebellar ataxia is caused by recessive mutations in mitochondrial
proteins Twinkle and Twinky’, Hum. Mol. Genet. 14(20), 2981–2990.
Nikkanen, J., Forsstrom, S., Euro, L., Paetau, I., Kohnz, R. A., Wang, L., Chilov, D., Viinamaki, J.,
Roivainen, A., Marjamaki, P., Liljenback, H., Ahola, S., Buzkova, J., Terzioglu, M., Khan, N. A.,
46
Pirnes-Karhu, S., Paetau, A., Lonnqvist, T., Sajantila, A., Isohanni, P., Tyynismaa, H., Nomura,
D. K., Battersby, B. J., Velagapudi, V., Carroll, C. J. and Suomalainen, A. (2016), ‘Mitochondrial
DNA Replication Defects Disturb Cellular dNTP Pools and Remodel One-Carbon Metabolism’, Cell
Metab. 23(4), 635–648.
Nsiah-Sefaa, A. and McKenzie, M. (2016), ‘Combined defects in oxidative phosphorylation and fatty
acid β-oxidation in mitochondrial disease’, Biosci. Rep. 36(2).
Nunnari, J. and Suomalainen, A. (2012), ‘Mitochondria: in sickness and in health’, Cell
148(6), 1145–1159.
Pilz, R. B., Willis, R. C. and Boss, G. R. (1984), ‘The influence of ribose 5-phosphate availability on
purine synthesis of cultured human lymphoblasts and mitogen-stimulated lymphocytes’, J. Biol. Chem.
259(5), 2927–2935.
Pohjoismaki, J. L., Goffart, S., Tyynismaa, H., Willcox, S., Ide, T., Kang, D., Suomalainen, A.,
Karhunen, P. J., Griffith, J. D., Holt, I. J. and Jacobs, H. T. (2009), ‘Human heart mitochondrial
DNA is organized in complex catenated networks containing abundant four-way junctions and repli-
cation forks’, J. Biol. Chem. 284(32), 21446–21457.
Qi, X., Lewin, A. S., Hauswirth, W. W. and Guy, J. (2003), ‘Optic neuropathy induced by reductions
in mitochondrial superoxide dismutase’, Invest. Ophthalmol. Vis. Sci. 44(3), 1088–1096.
Quiros, P. M., Mottis, A. and Auwerx, J. (2016), ‘Mitonuclear communication in homeostasis and stress’,
Nat. Rev. Mol. Cell Biol. 17(4), 213–226.
Ring, K. L., Tong, L. M., Balestra, M. E., Javier, R., Andrews-Zwilling, Y., Li, G., Walker, D., Zhang,
W. R., Kreitzer, A. C. and Huang, Y. (2012), ‘Direct reprogramming of mouse and human fibroblasts
into multipotent neural stem cells with a single factor’, Cell Stem Cell 11(1), 100–109.
Rugarli, E. I. and Langer, T. (2012), ‘Mitochondrial quality control: a matter of life and death for
neurons’, EMBO J. 31(6), 1336–1349.
Sanchez-Danes, A., Richaud-Patin, Y., Carballo-Carbajal, I., Jimenez-Delgado, S., Caig, C., Mora, S.,
Di Guglielmo, C., Ezquerra, M., Patel, B., Giralt, A., Canals, J. M., Memo, M., Alberch, J., Lopez-
Barneo, J., Vila, M., Cuervo, A. M., Tolosa, E., Consiglio, A. and Raya, A. (2012), ‘Disease-specific
phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s
disease’, EMBO Mol Med 4(5), 380–395.
Saraste, M. (1999), ‘Oxidative phosphorylation at the fin de sicle’, Science 283(5407), 1488–1493.
Schagger, H. and Pfeiffer, K. (2000), ‘Supercomplexes in the respiratory chains of yeast and mammalian
mitochondria’, EMBO J. 19(8), 1777–1783.
Shi, Y., Dierckx, A., Wanrooij, P. H., Wanrooij, S., Larsson, N. G., Wilhelmsson, L. M., Falkenberg,
M. and Gustafsson, C. M. (2012a), ‘Mammalian transcription factor A is a core component of the
mitochondrial transcription machinery’, Proc. Natl. Acad. Sci. U.S.A. 109(41), 16510–16515.
47
Shi, Y., Kirwan, P., Smith, J., Robinson, H. P. and Livesey, F. J. (2012b), ‘Human cerebral cortex devel-
opment from pluripotent stem cells to functional excitatory synapses’, Nat. Neurosci. 15(3), 477–486.
Smirnova, E., Griparic, L., Shurland, D. L. and van der Bliek, A. M. (2001), ‘Dynamin-related protein
Drp1 is required for mitochondrial division in mammalian cells’, Mol. Biol. Cell 12(8), 2245–2256.
Song, Z., Ghochani, M., McCaffery, J. M., Frey, T. G. and Chan, D. C. (2009), ‘Mitofusins and OPA1
mediate sequential steps in mitochondrial membrane fusion’, Mol. Biol. Cell 20(15), 3525–3532.
Spelbrink, J. N., Li, F. Y., Tiranti, V., Nikali, K., Yuan, Q. P., Tariq, M., Wanrooij, S., Garrido, N.,
Comi, G., Morandi, L., Santoro, L., Toscano, A., Fabrizi, G. M., Somer, H., Croxen, R., Beeson, D.,
Poulton, J., Suomalainen, A., Jacobs, H. T., Zeviani, M. and Larsson, C. (2001), ‘Human mitochondrial
DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein
localized in mitochondria’, Nat. Genet. 28(3), 223–231.
Suomalainen, A. and Battersby, B. J. (2017), ‘Mitochondrial diseases: the contribution of organelle stress
responses to pathology’, Nat. Rev. Mol. Cell Biol. .
Suomalainen, A. and Isohanni, P. (2010), ‘Mitochondrial DNA depletion syndromes–many genes, com-
mon mechanisms’, Neuromuscul. Disord. 20(7), 429–437.
Takahashi, K. and Yamanaka, S. (2006), ‘Induction of pluripotent stem cells from mouse embryonic and
adult fibroblast cultures by defined factors’, Cell 126(4), 663–676.
Tibbetts, A. S. and Appling, D. R. (2010), ‘Compartmentalization of Mammalian folate-mediated one-
carbon metabolism’, Annu. Rev. Nutr. 30, 57–81.
Timmis, J. N., Ayliffe, M. A., Huang, C. Y. and Martin, W. (2004), ‘Endosymbiotic gene transfer:
organelle genomes forge eukaryotic chromosomes’, Nat. Rev. Genet. 5(2), 123–135.
Titov, D. V., Cracan, V., Goodman, R. P., Peng, J., Grabarek, Z. and Mootha, V. K. (2016), ‘Com-
plementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio’,
Science 352(6282), 231–235.
Tortora, G. J. and Derrickson, B. (2012), Principles of Anatomy and Physiology, 13 edn, John Wiley
and Sons, Inc.
Touma, E. H. and Charpentier, C. (1992), ‘Medium chain acyl-CoA dehydrogenase deficiency’, Arch.
Dis. Child. 67(1), 142–145.
Tserng, K. Y., Jin, S. J., Kerr, D. S. and Hoppel, C. L. (1990), ‘Abnormal urinary excretion of unsatu-
rated dicarboxylic acids in patients with medium-chain acyl-CoA dehydrogenase deficiency’, J. Lipid
Res. 31(5), 763–771.
Turrens, J. F. (2003), ‘Mitochondrial formation of reactive oxygen species’, J. Physiol. (Lond.) 552(Pt
2), 335–344.
48
Tyynismaa, H., Carroll, C. J., Raimundo, N., Ahola-Erkkila, S., Wenz, T., Ruhanen, H., Guse, K.,
Hemminki, A., Peltola-Mj?sund, K. E., Tulkki, V., Oresic, M., Moraes, C. T., Pietilainen, K., Hovatta,
I. and Suomalainen, A. (2010), ‘Mitochondrial myopathy induces a starvation-like response’, Hum. Mol.
Genet. 19(20), 3948–3958.
Tyynismaa, H., Sembongi, H., Bokori-Brown, M., Granycome, C., Ashley, N., Poulton, J., Jalanko, A.,
Spelbrink, J. N., Holt, I. J. and Suomalainen, A. (2004), ‘Twinkle helicase is essential for mtDNA
maintenance and regulates mtDNA copy number’, Hum. Mol. Genet. 13(24), 3219–3227.
Vagelos, P. R., Alberts, A. W. and Martin, D. B. (1963), ‘Studies on the mechnism of activation of acetyl
coenzyme A carboxylase by citrate’, J. Biol. Chem. 238, 533–540.
Valentine, J. S. and Hart, P. J. (2003), ‘Misfolded CuZnSOD and amyotrophic lateral sclerosis’, Proc.
Natl. Acad. Sci. U.S.A. 100(7), 3617–3622.
Vierbuchen, T., Ostermeier, A., Pang, Z. P., Kokubu, Y., Sudhof, T. C. and Wernig, M. (2010), ‘Direct
conversion of fibroblasts to functional neurons by defined factors’, Nature 463(7284), 1035–1041.
Wang, Y., Mohsen, A. W., Mihalik, S. J., Goetzman, E. S. and Vockley, J. (2010), ‘Evidence for physical
association of mitochondrial fatty acid oxidation and oxidative phosphorylation complexes’, J. Biol.
Chem. 285(39), 29834–29841.
Williams, E. G., Wu, Y., Jha, P., Dubuis, S., Blattmann, P., Argmann, C. A., Houten, S. M., Amariuta,
T., Wolski, W., Zamboni, N., Aebersold, R. and Auwerx, J. (2016), ‘Systems proteomics of liver
mitochondria function’, Science 352(6291), aad0189.
Wonders, C. P. and Anderson, S. A. (2006), ‘The origin and specification of cortical interneurons’, Nat.
Rev. Neurosci. 7(9), 687–696.
Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell,
B., Scarpulla, R. C. and Spiegelman, B. M. (1999), ‘Mechanisms controlling mitochondrial biogenesis
and respiration through the thermogenic coactivator PGC-1’, Cell 98(1), 115–124.
Xia, G., Santostefano, K., Hamazaki, T., Liu, J., Subramony, S. H., Terada, N. and Ashizawa, T. (2013),
‘Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro’,
J. Mol. Neurosci. 51(2), 237–248.
Xia, J. and Wishart, D. S. (2016), ‘Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data
Analysis’, Curr Protoc Bioinformatics 55, 1–14.
Yakubovskaya, E., Chen, Z., Carrodeguas, J. A., Kisker, C. and Bogenhagen, D. F. (2006), ‘Functional
human mitochondrial DNA polymerase gamma forms a heterotrimer’, J. Biol. Chem. 281(1), 374–382.
Yang, M. Y., Bowmaker, M., Reyes, A., Vergani, L., Angeli, P., Gringeri, E., Jacobs, H. T. and Holt, I. J.
(2002), ‘Biased incorporation of ribonucleotides on the mitochondrial L-strand accounts for apparent
strand-asymmetric DNA replication’, Cell 111(4), 495–505.
49
Yang, S. Y., He, X. Y. and Schulz, H. (1987), ‘Fatty acid oxidation in rat brain is limited by the low
activity of 3-ketoacyl-coenzyme A thiolase’, J. Biol. Chem. 262(27), 13027–13032.
Yasukawa, T., Reyes, A., Cluett, T. J., Yang, M. Y., Bowmaker, M., Jacobs, H. T. and Holt, I. J.
(2006), ‘Replication of vertebrate mitochondrial DNA entails transient ribonucleotide incorporation
throughout the lagging strand’, EMBO J. 25(22), 5358–5371.
Ying, W. (2008), ‘NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation
and biological consequences’, Antioxid. Redox Signal. 10(2), 179–206.
Yoo, A. S., Sun, A. X., Li, L., Shcheglovitov, A., Portmann, T., Li, Y., Lee-Messer, C., Dolmetsch, R. E.,
Tsien, R. W. and Crabtree, G. R. (2011), ‘MicroRNA-mediated conversion of human fibroblasts to
neurons’, Nature 476(7359), 228–231.
Zhang, X., Huang, C. T., Chen, J., Pankratz, M. T., Xi, J., Li, J., Yang, Y., Lavaute, T. M., Li, X. J.,
Ayala, M., Bondarenko, G. I., Du, Z. W., Jin, Y., Golos, T. G. and Zhang, S. C. (2010), ‘Pax6 is a
human neuroectoderm cell fate determinant’, Cell Stem Cell 7(1), 90–100.
Zuchner, S., Mersiyanova, I. V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J., Dadali, E. L., Zappia, M.,
Nelis, E., Patitucci, A., Senderek, J., Parman, Y., Evgrafov, O., Jonghe, P. D., Takahashi, Y., Tsuji,
S., Pericak-Vance, M. A., Quattrone, A., Battaloglu, E., Polyakov, A. V., Timmerman, V., Schroder,
J. M., Vance, J. M. and Battologlu, E. (2004), ‘Mutations in the mitochondrial GTPase mitofusin 2
cause Charcot-Marie-Tooth neuropathy type 2A’, Nat. Genet. 36(5), 449–451.
50
